Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
06/2009 | Recent  |  14: Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions June invention type 06/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
06/25/2009 > patent applications in patent subcategories. invention type

20090163405 - Angiogenic peptides and uses thereof: A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090163417 - Activin-actrii antagonists and uses for increasing red blood cell levels: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Ropes & Gray LLP

20090163407 - Compositions and methods for altering wnt autocrine signaling: The present invention relates to compounds and methods for treating cancers in which the autocrine Wnt canonical signaling pathway is activated. In particular, there is provided a method for inhibiting growth of a tumor cell or sensitizing a cancer cell to treatment by contacting such a tumor cell with a... Agent: Darby & Darby P.C.

20090163406 - Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells: In one aspect, the invention provides composition and methods for the diagnosis, prognosis and treatment of tumors and cancers, e.g., brain cancers. In one aspect, the invention provides compositions and methods for inhibiting the growth, proliferation, differentiation and/or survival of a neural stem cell or a cancer cell, or progenitor... Agent: Morrison & Foerster LLP

20090163412 - Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin.... Agent: King & Spalding

20090163413 - Dental products comprising bone growth enhancing peptide: Dental products such as toothpastes, mouthwash and dental floss are disclosed which products are enhanced by having dissolved, dispersed or coated thereon a compound which promotes bone growth. Preferred compounds are peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing an integrin binding... Agent: Bozicevic, Field & Francis LLP

20090163423 - Exendins and exendin agonist analogs to regulate gastrointestinal motility: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090163419 - Human growth hormone aqueous formulation: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.... Agent: Genentech, Inc.

20090163414 - In-vitro method for screening accessible biological markers in pathological tissues: The present invention refers to an in vitro method for screening specific disease biological markers which are accessible from the extracellular space in pathologic tissues comprising the steps of: immersing a native pathologic tissue sample in a solution containing a labelling reagent for labelling proteins, wherein accessible proteins are labelled... Agent: Knobbe Martens Olson & Bear LLP

20090163411 - Long acting vegf inhibitors and methods of use: Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom... Agent: Sheridan Ross PC

20090163410 - Novel peptides and the biological use thereof: The invention relates to novel purified insulated peptides, which exhibit, in particular, Nef protein-binding properties and are characterised in that they contain an amino acid sequence of a formula SEQ ID No 1: W-P-a-W-L-P, wherein a is selected from W, A, S or D.... Agent: Nixon & Vanderhye, PC

20090163415 - Nt-probnp, probnp and bnp immunoassays, antibodies and stable standard: The present invention provides antibodies against glycosylated proBNP and NT-proBNP. The antibodies are suitable for precise immunodetection of both of the proteins in human blood. The glycosylated forms of proBNP and NT-proBNP may be utilized as an antigen for antibody generation as well as a calibrator or immunological standard in... Agent: Birch Stewart Kolasch & Birch

20090163418 - Resuscitation fluid: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood... Agent: Andrews Kurth LLP Intellectual Property Department

20090163421 - Room temperature stable, lyophilized natriuretic peptide formulations: Lyophilized pharmaceutical compositions comprise a natriuretic peptide, a buffer and a bulking agent that are stable at room temperature. Preferably, for a fill volume of 1 mL (pre-lyophilization), the total cake mass, post-lyophilization, is 30-175 mg. Preferably, the natriuretic peptide is ularitide or a pharmaceutically acceptable salt thereof. Various embodiments... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090163408 - Salicylanilides enhance oral delivery of therapeutic peptides: This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical... Agent: Weaver Austin Villeneuve & Sampson LLP

20090163424 - Soluble tumor necrosis factor receptor treatment of medical disorders: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.... Agent: Immunex Corporation Law Department

20090163420 - Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto: The present invention relates to immunogenic but non-depositing-forming polypeptides or peptides homologous to amyloid β, prion, amylin or α-synuclein which can be used alone or conjugated to an immunostimulatory molecule in an immunizing composition for inducing an immune response to amyloid β peptides and amyloid deposits, to prion protein and... Agent: Darby & Darby P.C.

20090163422 - Three-dimensional structure of the apobec 2 structure, uses thereof, and methods for treating chronic and infectious diseases: Three-dimensional structure of APOBEC-2 and other structure models of APOBEC proteins obtained by computer modeling that bear similarity with a root-mean-square deviation (RMSD) of 2.0 with the APOBEC-2 monomer, dimer or tetramer. Uses of the three-dimensional structure of APOBEC-2 and models of APOBEC proteins particularly for structure-based drug design of... Agent: Greenberg Traurig LLP (la)

20090163409 - Trappin-2 (elafin) inhibits hiv: In sub-Saharan Africa, the vast majority of HIV transmission occurs through heterosexual contact, therefore, the initial site of HIV infection occurs within the genital tract. In a cohort of HIV-highly exposed sex workers we have identified a select group of individuals who epidemiologically and clinically appear to be HIV-resistant. Studies... Agent: Ade & Company Inc.

20090163416 - Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natured glucocorticoids.... Agent: Alan F. Feeney, Esq. Biomeasure, Incorporated

20090163425 - Peptide inhibiting angiotensin converting enzyme: The invention provides a peptide having an activity of inhibiting angiotensin-converting enzyme (ACE), and a food and drink and/or a pharmaceutical composition containing the peptide.... Agent: Sughrue-265550

20090163426 - Tissue specific prodrugs: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic... Agent: Paul, Hastings, Janofsky & Walker LLP

20090163427 - Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders: The pharmaceutical composition is a combination of hydrolytic lignin with moisture of 55% to 65% consisting of the particles measuring 0.15 mm to 0.55 mm, a 45% to 55% aqueous lactulose solution, and a 50% to 55% aqueous oligosaccharide solution at the following ingredient ratio (weight percent): an aqueous lactulose... Agent: The Nath Law Group

20090163428 - Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful... Agent: Morgan Lewis & Bockius LLP

20090163433 - Anthelmintic and/or insecticide development: The use of a nucleic acid molecule encoding FAS in a nematode or arthropod, or a fragment or variant thereof, to identify or produce FAS as a target for: endectocide; anthelmintic and/or insecticide; development.... Agent: Knobbe Martens Olson & Bear LLP

20090163431 - Compositions and methods for modulation of pdx-1: Methods and compositions for inhibiting PDX-1 are provided according to the present invention. An anti-PDX-1 agent included in inventive methods and compositions includes an antibody, an aptamer, an antisense oligonucleotide, a ribozyme and/or an inhibitory compound. Methods of inhibiting PDX-1 expression in a tumor cell are provided by the present... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090163430 - Functions and targets of let-7 micro rnas: The present invention concerns methods and compositions for treating or assessing treatment of diseases related to mis-expression of genes or genetic pathways that can be modulated by let-7. Methods may include evaluating patients for genes or genetic pathways modulated by let-7, and/or using an expression profile to assess the condition... Agent: Fullbright & Jaworski L.L.P.

20090163438 - Gankyrin: Gankyrin having the amino acid sequence as set forth in SEQ ID NO: 2, or modified gankyrin comprising an amino acid sequence modified by the deletion and/or addition of one or a plurality of amino acids and/or the substitution with other amino acids in the amino acid sequence of SEQ... Agent: Foley And Lardner LLP Suite 500

20090163436 - Methods for delivery of nucleic acids: This invention features methods and compositions for delivery of nucleic acids (e.g., DNA, RNA, PNA, and hybrids thereof) to cells. The nucleic acid delivery complexes of the invention permit biologically active nucleic acids to be delivered to cells and organisms in vitro and in vivo in a manner and form... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090163434 - Mir-20 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-20a, using miR-20a to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090163435 - Mir-200 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-200, using miR-200 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090163429 - Rna aptamers and methods for identifying the same: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.... Agent: King & Spalding

20090163437 - Steady-state subcutaneous administration of aptamers: An improved method of administration of an aptamer and modulator system to regulate blood coagulation in a host is provided wherein the aptamer is administered subcutaneously and the modulator is administered either subcutaneously or intravenously. This method for sustained aptamer activity using intermittent subcutaneous injections further allows for titrated modulation... Agent: King & Spalding

20090163432 - Therapeutic agent for corneal diseases: The present invention relates to a treatment agent for a disease or a disorder caused by a reduction in corneal endothelial cells, comprising as an active component at least one nucleic acid molecule inhibiting the expression of a connexin 43 gene.... Agent: Kratz, Quintos & Hanson, LLP

20090163441 - Hyaluronic acid binary mixtures and therapeutic use thereof: The present invention is related to hyaluronic acid compositions consisting in a binary mixtures of hyaluronic acid samples having mainly different weight-average molecular weight and then different rheological properties in aqueous solution. The resulting compositions have demonstrated peculiar rheological behaviour with a balance between viscosity and viscoelasticity. Accordingly, these compositions... Agent: Squire, Sanders & Dempsey L.L.P.

20090163440 - Ion-channel regulator compositions and methods of using same: A composition and method for the treatment of degenerative joint disease is disclosed. The composition includes a combination of a first ion-channel regulator, at least a second ion-channel regulator, and a pharmaceutically acceptable carrier suitable for intraarticular injection. Methods and kits for treating a degenerative joint disease are also disclosed.... Agent: Goodwin Procter LLP Patent Administrator

20090163439 - Methods of using beta glucan as a radioprotective agent: The invention relates to methods for treating and preventing radiation and/or chemotherapy related injury and/or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090163442 - Treatment of cancer with 2-deoxygalactose: 2-Deoxygalactose and its analogs can be used to treat cancer and to improve patient outcome when administered in therapeutically effective doses alone or in combination with other anti-cancer drugs or with surgical resection or radiation therapy.... Agent: Edwards Angell Palmer & Dodge LLP

20090163443 - novel compound, useful for pancreatic lipase inhibition and the process for isolation thereof: The present invention relates to a novel, Nonadeca-6-enoic acid-3-(hexadecyloxy-hydroxy-thiophosphoryloxy)-quinoxalin-2-yl ester designated as streptolipin, useful for pancreatic lipase inhibition, isolated from the culture of Streptomyces vayuensis strain N2 having molecular formula (1) and a process for the preparation thereof.... Agent: Ladas & Parry LLP

20090163444 - Phospho-indoles as hiv inhibitors: 3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.... Agent: Jones Day

20090163446 - Diazonamide analogs with improved solubility: Diazonamide A analogs, and the salts, esters and conjugates thereof, having improved aqueous solubility are provided. Also provided are pharmaceutical compositions, and methods for preparing and using such compounds and compositions for the treatment of proliferative diseases.... Agent: Morrison & Foerster LLP

20090163445 - Synergistic microbicidal compositions: This invention relates to synergistic combinations of selected microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) 5-Chloro-2-methyl-4-isothiazolin-3-one+2-Methyl-4-isothiazolin-3-one, :(b) Methyl-4-isothiazolin-3-one, or (c) 1,2-Benzisothiazolin-3-one with one... Agent: Rohm And Haas Company Patent Department

20090163447 - Compositions for drug administration: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.... Agent: Dla Piper LLP (us)

20090163448 - Diagnosis and treatment of human dormancy-related sequellae: New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects. HDS includes fibromyalgia, chronic fatigue, cancer, autoimmune disease, obesity and related dormancy conditions. Dormancy and HDS-related sequellae are... Agent: Borson Law Group, PC

20090163449 - Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives: Sulfo-polyester powders and sulfo-polyester blend powders, the incorporation of carriers and/or actives, and methods of making the powders as well as dispersions employing these powders.... Agent: Brett L. Nelson Eastman Chemical Company

20090163450 - Combinations comprising a prostaglandin and uses thereof: The invention relates to a combination comprising (a) a compound selected from the class of prostaglandins and (b) a compound selected from the class of tubulin/microtubule interfering agents and/or (c) a compound selected from the class of cyclooxygenase inhibitors.... Agent: Millen, White, Zelano & Branigan, P.C.

20090163451 - Methods for treating visceral pain: The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT1B or 5HT1D receptor agonist, (e.g., a triptan). These methods can be used, for example, to treat a human suffering from visceral pain secondary to an underlying disease of a visceral organ, such... Agent: Clark & Elbing LLP

20090163452 - Compositions and methods for lowering serum cholesterol: The invention provides a method for lowering circulating LDL-cholesterol or total cholesterol in a human in need thereof, comprising: orally administering to the human a therapeutically effective amount of a statin and vitamin D daily for at least about 6 weeks, wherein the vitamin D is administered by one or... Agent: Morrison & Foerster LLP

20090163453 - Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds: The present invention relates to a method for preventing, treating, or ameliorating gastrointestinal and bladder disorders in a patient receiving a chemotherapy or radiation therapy comprising administering to the patient a therapeutically effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090163454 - Methods of step-down hormone treatment: The present invention relates to methods of step-down hormone treatment in which an estrogen and progestin combination regimen is administered for one or more cycles prior to administration of a lower dose hormone regimen containing a lower daily dosage amount of estrogen and/or progestin.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090163455 - Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090163456 - Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists: a

20090163457 - Compositions and methods for delivering a biologically active agent: The invention relates to codrugs having improved properties, methods for preparing and administering them, and methods of formulating and administering the codrugs as pharmaceutical preparations. In certain embodiments, the codrugs can be locally administered to deliver the constituent biologically active compound in a sustained-release fashion, reducing systemic concentrations of the... Agent: Ropes & Gray LLP

20090163458 - Compositions and methods for treating parkinson's disease and related disorders: The present disclosure relates generally to methods and compositions for treating symptoms of Parkinson's disease and/or other movement disorders. More particularly, the present disclosure describes a method for treating symptoms of Parkinson's disease and related disorders by administering a composition comprising one or more of the following active agents; estradiol,... Agent: King & Spalding

20090163460 - Diagnostics and therapeutics for early-onset menopause: A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090163459 - Use of 24-nor-udca: The present invention relates to the use of nor-ursodeoxycholic acid for the manufacture of a drug for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases.... Agent: Fulbright & Jaworski L.L.P.

20090163461 - Ligand for vesicular acetylcholine transporter: wherein R1 and R2 are as defined in the specification, or a salt thereof, which is useful as a reagent (radiotracer) for VAChT mapping and the like, and can be used for positron emission tomography (PET), and a production method of the compound. Moreover, the present invention provides a diagnostic... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090163466 - Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.... Agent: Morgan, Lewis & Bockius, LLP

20090163468 - Fused bicyclic mtor inhibitors: e

20090163467 - New compounds:

20090163469 - Organic compounds:

20090163470 - Thiazolylidine urea and amide derivatives and methods of use thereof: The invention relates to novel thiazolylidine urea and amide derivatives that are PAMs of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20090163464 - Benzothiazole and benzooxazole derivatives and methods of use: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.... Agent: Paul D. Yasger Abbott Laboratories

20090163462 - Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation: m

20090163463 - Organic compounds:

20090163465 - Pyrimidines as plk inhibitors:

20090163472 - Mineralocorticoid receptor antagonists and methods of use: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically... Agent: Eli Lilly & Company

20090163471 - Tropane compounds:

20090163473 - (pyrido/thieno)-[f]-oxazepine-5-one derivatives: wherein R1, R2 and R3 are independently H or (C1-4)alkyl; Ar represents a fused thiophene or pyridine ring optionally substituted with one or more substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, CF3, halogen, nitro, cyano, NR4R5, NR4COR6, and CONR4R5; R4 and R5 are independently H or (C1-4)-alkyl; or R4 and R5... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090163474 - Fxr agonists for the treatment of nonalcoholic fatty liver and cholesterol gallstone diseases: Provided are certain methods of treating nonalcoholic fatty liver disease with farnesoid X receptor agonists. Also provided are certain methods of modulating levels of keratinocyte-derived chemokine (KC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cytokeratin 18 (CK-18), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-14 (MMP-14), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Cytochrome... Agent: Wyeth/finnegan Henderson, LLP

20090163475 - Crystalline form of benzazepinium maleate derivative: The present invention relates to a novel polymorphic form of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium maleate and a pharmaceutically acceptable solvate thereof, pharmaceutical formulation, process for its preparation and its use in medicine, in particular its use as an antipsychotic agent.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090163476 - N-phenyl benzamide derivatives as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090163477 - Phthalazinone derivatives: o

20090163478 - Salts and crystal modifications thereof: The invention relates to salts of 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing such salts and crystalline forms.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090163479 - Use of taurolidine to treat tumors: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090163480 - Modified amino acids, pharmaceuticals containing these compounds and method for their production: A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090163481 - Ppar-delta ligands and methods of their use: The disclosure provides compounds, compositions, and methods for modulating PPARδ receptor. In one embodiment, the compounds of the disclosure comprise a tri-substituted thiazole group. The substituent at the 2-position of the thiazole group provides steric bulk to the compounds. The compounds, compositions, and methods may be useful, for example, in... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090163482 - Tetralines antagonists of the h-3 receptor: This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula (I) a process of en preparation of a compound of formula (I), a method of treatment of a disorder or condition that may... Agent: Pfizer Inc Steve T. Zelson

20090163484 - Pharmaceuticals containing fluoroquinolones: The invention relates to pharmaceutical formulations in liquid form, containing fluoroquinolones and antioxidative sulphur compounds. The formulations are particularly suitable for parenteral uses and are distinguished, inter alia, by good tolerance.... Agent: Bayer Healthcare LLC

20090163483 - Use of neonicotinoids in pest control: a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with a nitroimino- or nitroguanidino-compound, especially with thiamethoxam, characterized in that a pesticidal composition comprising a nitroimino- or nitroguanidino-compound in... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090163485 - Heteroaryl derivatives as orexin receptor antagonists: Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090163486 - Novel 2-arylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals: The present invention relates to 2-arylthiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof... Agent: Millen, White, Zelano & Branigan, P.C.

20090163487 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under... Agent: Morrison & Foerster LLP

20090163488 - Fused heterocycle derivatives and use thereof: e

20090163489 - Inhibitors of pi3 kinase:

20090163490 - Pyrrolopyrimidine derivatives used as hsp90 inhibitors: Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk1-(Z)m-(Alk2)n-Q wherein X is —O—, —S— —S(O)—, SO2—, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—,... Agent: Banner & Witcoff, Ltd.

20090163491 - Substituted 8-[6-amino-3pyridyl]xanthines: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Clinical Data, Inc.

20090163495 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases: e

20090163494 - Protein kinase inhibitors:

20090163492 - Substituted oxindole derivatives, drugs containing said derivatives and the use thereof: The invention relates to novel oxindol derivative of general formula (I), wherein substituents R1, R2, A, B and Y are such as defined in a claim 1. Drugs containing said derivatives and the use thereof for preventing and/or treating vassopress- and/or oxytocin-dependent-diseases are also disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090163493 - Benzene, pyridine, and pyridazine derivatives: wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions... Agent: Pfizer Inc

20090163496 - Antibacterial agents: e

20090163498 - Aryl sulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated... Agent: Brinks Hofer Gilson & Lione

20090163497 - Compounds useful as antagonists of ccr2: The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and... Agent: Millennium Pharmaceuticals, Inc.

20090163501 - Aurora kinase modulators and method of use: wherein A1, A2, C1, C2, D, L1, L2, Z and R3, R4, R6, R7 and R8 are defined herein, which are capable of modulating Aurora kinase protein activity, thereby influencing various disease states and conditions related to the activities of Aurora kinase proteins. For example, the compounds are capable of... Agent: Amgen Inc.

20090163500 - Compositions and methods for treating lysosomal disorders: The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.... Agent: Wilson Sonsini Goodrich & Rosati

20090163499 - Imidazole-substituted arylamides as p2x3 and p2x2/3 antagonists: e

20090163502 - Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090163503 - Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors: Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.... Agent: Scully Scott Murphy & Presser, PC

20090163504 - Method for healing a wound using a phosphodiesterase type five inhibitor: A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as a phosphodiesterase type five inhibitor and pharmaceutically acceptable salts thereof.... Agent: King & Partners, PLC

20090163505 - Amino-heteroaryl-containing prokineticin 1 receptor antagonists: m

20090163506 - Urea-compounds active as vanilloid receptor antagonists for the treatment of pain:

20090163507 - Synthesis of naturally occuring ecteinascidins and related compounds: Ecteinascidin compounds with a quinone ring for ring E are active as anti-cancer agents. Related processes and compounds are provided.... Agent: Fish & Richardson PC

20090163508 - Amide compound: t

20090163509 - Method for healing a wound using an alpha-adrenergic antagonist: A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as an alpha-adrenergic antagonist and pharmaceutically acceptable salts thereof.... Agent: King & Partners, PLC

20090163510 - Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides: The invention described herein relates to mutant SRC kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant SRC kinase proteins.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090163511 - Carboxamide, sulfonamide and amine compounds and methods for using the same: e

20090163512 - Spiroindolinone derivatives:

20090163513 - Process for ziprasidone using novel intermediates:

20090163514 - Benzisoxazole piperazine compounds and methods of use thereof: The invention includes benzisoxazole piperazine compositions and methods of using them for modulating sleep.... Agent: Eli Lilly & Company

20090163515 - Compounds which bind to the active site of protein kinase enzymes: The present invention relates to a compound and a group of compounds which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular... Agent: Martin Savitzky Law Offices Of Martin Savitzky Esq.

20090163517 - Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives: wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090163516 - Carboxamides for controlling undesired micro-organisms in plant protection: e

20090163518 - Novel compounds: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20090163519 - Dosing regimen associated with long acting injectable paliperidone esters: The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.... Agent: Philip S. Johnson Johnson & Johnson

20090163520 - Mnk1 or mnk2 inhibitors: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.... Agent: Lowrie, Lando & Anastasi, LLP

20090163521 - Novel pyrazolopyrimidinone derivatives: The present invention relates to novel pyrazolopyrimidinones of the general formula (I), their derivatives, their analogs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrazolopyrimidinones derivatives of the general formula (I).... Agent: Oliff & Berridge, PLC

20090163522 - Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same: The invention relates to derivatives of pyrido[2,3-d]pyrimidine, to the preparation thereof, and to the therapeutic application of the same.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090163523 - Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor: The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination.... Agent: Novartis Corporate Intellectual Property

20090163524 - Novel protein kinase b inhibitors - 060: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods... Agent: Astrazeneca R&d Boston

20090163525 - Substituted quinazolines with anti-cancer activity: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20090163526 - Process for the preparation of an anti microbial extract from leaves of the plant callistemon rigidus: A process for the preparation of an antimicrobial extract from leaves of the plant Callistemon rigidus by cold extract using organic solvents selected from methanol, ethanol, chloroform, dichlorom ethane, hexane, diethyl and ether, concentrating the filtrate in vacuo to obtain the crude extract.... Agent: The Webb Law Firm, P.C.

20090163527 - Spiropiperidines for use as tryptase inhibitors: p

20090163528 - Pharmaceutical composition having analgesic effects: The pharmaceutical compositions having analgesic effect referred to in this invention are composed of the aconitine ingredients as the active medical ingredients and other acceptable auxiliary ingredients. The active medical ingredients shall at least include the fuziline compound of Formula (I). The drugs exert desirable analgesic effect with low toxicity.... Agent: Matthias Scholl

20090163529 - Identifying therapeutic compounds based on their physical-chemical properties: The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to... Agent: Morrison & Foerster LLP

20090163530 - Fast dissolving orally consumable films: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer such as pullulan. Edible films are disclosed that include pullulan and antimicrobially effective amounts of the essential oils thymol, methyl salicylate, eucalyptol and menthol. The edible films are effective at killing the plaque-producing germs... Agent: Evan J. Federman Legal Division

20090163531 - Use of tiotropium salts in the treatment of severe persistent asthma: The instant invention relates to the use of tiotropium salts for the manufacture of a medicament for the treatment of patients suffering from severe persistent asthma.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090163533 - 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases: Pyrazolo[3,4-c] ring compounds of Formula (I), e.g., pyrazolo[3,4-c]pyridines, pyrazolo[3,4-c]quinolines, 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and pyrazolo[3,4-c]naphthyridines, substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and... Agent: Wolf Greenfield & Sacks, P.C.

20090163532 - Aqueous gel formulations containing immune response modifiers: Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines,... Agent: Wolf Greenfield & Sacks, P.C.

20090163534 - Indolizine derivatives: Compounds of formula (I) are ligands of the CRTH2 receptor and are useful in the treatment of respiratory disease: Formula (I) wherein R1, R2, R3 and R4 each independently are hydrogen, C1C6alkyl, fully or partially fluorinated C1C6alkyl, halo, —S(O)nR10, —SO2N(R10)2, —N(R10)2, —C(O)N(R10)2, —NR10C(O)R9, —CO2R10, —C(O)R9, —NO2, —CN or —OR11; wherein... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090163535 - Substituted heteroarylalkanoic acids: Disclosed are substituted heteroarylalkanoic acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090163536 - Methods and compounds for treatment of clostridium based infection: Methionyl tRNA synthetase inhibitors (MetRS) are provided for use in therapy as antibacterial agents in Clostridium based infection.... Agent: Swanson & Bratschun, L.L.C.

20090163538 - Tetrahydropyridothiophenes for use in the treatment of cancer: Compounds of formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20090163537 - Thienopyridinone compounds and methods of treatment: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux... Agent: Goodwin Procter LLP Patent Administrator

20090163539 - Enantiomer of tenatoprazole and the use thereof in therapy: This invention relates to optically active substances of tenatoprazole, (+) and (−) -5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent.... Agent: Leydig Voit & Mayer, Ltd

20090163540 - Quinine sulfate polymorphs, processes of preparing, compositions and uses thereof: Disclosed are new quinine sulfate polymorphs, methods of making the polymorphs as well as formulations prepared therefrom and uses thereof.... Agent: Cantor Colburn, LLP

20090163541 - Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine: s

20090163542 - 5-ht7 receptor antagonists: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20090163543 - Histone deacetylase inhibitors and methods of use thereof: One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090163545 - Method for altering the lifespan of eukaryotic organisms: A method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using... Agent: Hodgson Russ LLP The Guaranty Building

20090163544 - Use of nk-3 receptor antagonists for the treatment of nausea and vomiting: This invention relates to the treatment or prevention of nausea and/or vomiting by the administration of a NK-3 receptor antagonist.... Agent: Merck And Co., Inc

20090163546 - Diacylglycerol acyltransferase inhibitors: i

20090163547 - Indene derivatives, their preparation and use as medicaments: The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds of formula (I) show affinity for 5-HT6 receptors and are, therefore, effective for treating diseases mediated by... Agent: Ostrolenk Faber Gerb & Soffen

20090163548 - Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second... Agent: Jones Day

20090163549 - Pharmaceutical composition comprising an amide derivative: The present invention provides a novel modulator of the TRPV1-receptor function, comprising a compound of the formula; wherein ring A is an optionally substituted carbocycle or heterocycle, ring B is an optionally substituted benzene ring or an optionally substituted 6-membered heteroaromatic ring containing N atom, a dashed line means existence... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090163550 - Retinoid-containing sustained release intraocular implants and related methods: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Allergan, Inc.

20090163553 - Benzimidazole compound crystal: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090163552 - Carboxyl- or hydroxyl-substituted benzimidazole derivatives: n

20090163551 - Compositions and methods for treating diseases: This invention relates to methods for treating, preventing and/or managing gastric injury, e.g., NSAID-induced gastric injury in a subject including administering to the subject tegaserod, alone or in combination with a proton pump inhibitor. Also provided are compositions and kits for use in methods of the invention.... Agent: Novartis Corporate Intellectual Property

20090163554 - Use of cni-od formulations for controlling white fly: Method of controlling eggs and nymphal stages of whitefly by the spray application of oil-based suspension concentrates containing at least one insecticide from the neonicotinyl series, at least one penetrant from the alcohol ethoxylate series, at least one vegetable oil, at least one nonionic surfactant and, if appropriate one or... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090163555 - Synthesis and uses of pyroglutamic acid derivatives: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing... Agent: Moore & Van Allen PLLC

20090163556 - Glycinamide derivatives as raf-kinase inhbitors: wherein A, D, and B are as herein defined, as well as the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition, and a method of treatment comprising administering said pharmaceutical composition to... Agent: Millen, White, Zelano & Branigan, P.C.

20090163557 - Cannabinergic lipid ligands: One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability.... Agent: Alix Yale & Ristas LLP

20090163558 - Substituted methyl aryl or heteroaryl amide compounds: X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions... Agent: Scully Scott Murphy & Presser, PC

20090163559 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20090163560 - Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives: e

20090163561 - Amorphous metaxalone and amorphous dispersions thereof: The present invention provides various amorphous forms of the compound metaxalone (I), such as solid amorphous metaxalone and amorphous dispersions comprising metaxalone. The present invention further provides pharmaceutical compositions comprising these amorphous forms, and methods of their preparation. The present invention additionally provides methods of treating painful conditions (e.g., such... Agent: Choate, Hall & Stewart LLP

20090163562 - Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6- yl)methoxy]phenyl]propionic acid or salt thereof: An oral composition contains 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic acid or a salt thereof and polyvinylpyrrolidone is advantageous as an oral medication composition (1) which can be produced without requiring new manufacturing equipment; (2) which can be produced with simple steps; (3) which maintains stable solubility even with changes in the pH of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090163563 - Phorboxazole compounds and methods of their preparation: Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.... Agent: Woodcock Washburn LLP

20090163564 - Translational dysfunction based therapeutics: Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eIF4E. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090163565 - Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof: Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.... Agent: Abelman, Frayne & Schwab

20090163566 - Imidazole derivatives and their use for modulating the gabaa receptor complex: This invention relates to novel imidazole derivatives of the general formula (I): pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and... Agent: Birch Stewart Kolasch & Birch

20090163568 - Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090163567 - Germicide composition for agricultural and gardening applications and method for controlling plant disease: a

20090163569 - Process for the production of amides: The present invention relates to a process for the preparation of compounds of formula (I) wherein R1 and R2 are each independently of the other hydrogen or C1-C5alkyl and R3 is CF3 or CF2H, by a) reaction of a compound of formula (II) wherein R1 and R2 are as defined... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090163570 - Bladder cancer treatment and methods: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.... Agent: K&l Gates LLP

20090163571 - Pharmaceutical for use in the treatment of ureterolithiasis: The present invention provides pharmaceutical compositions useful for relieving pain caused by ureteral calculi, facilitating exclusion of ureteral calculi or the like. That is, the present invention provides a pharmaceutical composition for the treatment of ureteral lithiasis, which comprises as an active ingredient an indoline derivative represented by the following... Agent: Sughrue Mion, PLLC

20090163572 - Cooling compounds: e

20090163573 - Compositions and methods for enhancing protein accretion in skeletal muscle: A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and an effective amount of glutamine or derivative of glutamine, wherein the ingredients act substantially simultaneously to increase protein synthesis and inhibit protein degradation in skeletal muscle, via enhanced expression of heat shock proteins in... Agent: Torys LLP

20090163574 - Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same: The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound,... Agent: Frommer Lawrence & Haug

20090163575 - Solvent systems for pour-on formulations for combating parasites: This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on... Agent: Judy Jarecki-black Merial Limited

20090163576 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7... Agent: Wellstat Management Company. LLC

20090163577 - Methods and compositions for antagonizing anti-apoptotic bcl-2-family proteins: The cytotoxic natural product gambogic acid (GA) competes for BH3 peptide binding sites on several anti-apoptotic members of the Bcl-2 family of proteins and neutralizes the ability of these proteins to suppress release of apoptogenic proteins from isolated mitochondria. Structure-function analysis of GA using analogs suggested a general correlation between... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090163580 - Anti-aging composition containing resveratrol and method of administration: Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic... Agent: Gabor L. Szekeres Law Offices Of Gabor L. Szekeres

20090163578 - Novel modification of immunomodulatory protein: Methods of inhibiting annexin I induced apoptosis by contacting a cell population containing a TRPM7/ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090163579 - Novel use of nutraceutical compositions: The use of at least one component selected from the group consisting of EGCG, hydroxytyrosol, resveratrol and derivatives, metabolites or analogues thereof in the manufacture of a nutraceutical composition for the prevention and treatment of muscle wasting leading to muscle loss, atrophy and other associated muscle disorders in animals, in... Agent: Nixon & Vanderhye, PC

20090163581 - Pharmaceutical products for treating neoplastic disease and inflammation: Disclosed in certain embodiments is a pharmaceutical formulation and a functional food comprising a pharmaceutical ingredient comprising an active agent combination comprising flavonoids and tocotrienols in a ratio of about 75:25 to about 95:5 and at least one pharmaceutically acceptable excipient and methods to treat neoplastic diseases and inflammation.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090163582 - Stable pesticide concentrates and end-use emulsions: Pesticide concentrates are provided containing an emulsifier that is an EPA list 4 inert and is a polyglycerol fatty acid ester, a sorbitan fatty acid ester or a combination thereof, a pesticide and a solvent that is either a EPA list 3 inert of acetyl ester, EPA list 4 inert... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090163583 - Process and an apparatus for producing episesamin-rich compositions: There are provided a process and an apparatus which comprise the step of applying epimerization to sesamin or a sesamin-containing composition so that at least part of the sesamin is converted to episesamin and the step of selectively crystallizing episesamin by recrystallization and by means of which a composition that... Agent: Drinker Biddle & Reath (dc)

20090163584 - Therapeutic agent for renal failure: A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also a method for treatment of renal failure using the same.... Agent: Ip Group Of Dla Piper US LLP

20090163586 - Bis-(sulfonylamino) derivatives in therapy 205: wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090163585 - Carbosulfane-based pesticidal compositions, process for preparing same, process for controlling insects/mites/nematodes, and use of said compositions: The present invention relates to pesticidal compositions comprising 2,3-dihydro-2,2-dimethylbenzofuran-7-yl(dibutylaminothio)methylcarbamate, namely benzofuranyl methylcarbamate, commonly known as carbosulfane, of structural formula (I). The present invention deals more particularly with compositions comprising this active compound at a high concentration, which makes it the most economical product for sale, more stable during storage and... Agent: Alston & Bird LLP

20090163587 - Ester prodrugs of prostratin and related phorbol compounds: Ester prodrugs of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics, wherein the phorbol compounds are derivatized with a -x-o-c(o)-R′ group linked to the 6-carbon of the phorbol residue.... Agent: Dechert LLP

20090163588 - Aniline derivatives as selective androgen receptor modulators: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090163589 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090163590 - Process for producing refined avocado oil rich in triglycerides, and oil obtainable by said process: The present invention concerns a process for producing refined avocado oil rich in triglycerides. The invention also pertains to refined avocado oil rich in triglycerides obtainable by said process. Advantageously, the refined avocado oil of the invention contains a sterols-enriched unsaponifiable fraction. Advantageously, the refined avocado oil of the invention... Agent: Birch Stewart Kolasch & Birch

20090163591 - Use of sugar phosphates, sugar phosphate analogs, amino acids and/or amino acid analogs for modulating the glucolysis-enzyme complex, the malate asparate shuttle and/or the transaminases: The invention relates to methods for the treatment of tumors and/or for immune suppression and/or sepsis by modulating the association of the glycolysis enzyme complex/M2-PK and/or by inhibition of transaminases and/or separation of the binding of the malate dehydrogenase to p36 comprising administering a pharmaceutical composition comprising a substance selected... Agent: Mayer & Williams PC

20090163592 - Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090163593 - Amines that inhibit a mammalian anandamide transporter, and methods of use thereof: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which... Agent: Jones Day

20090163594 - Triple assay system for identifying substrate selectivity of gamma secretase inhibitors: The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a substrate specific manner. The invention provides an isolated cell wherein the cell stably expresses APP and at least one gamma secretase substrate other than APP. The invention provides assays and methods comprising contacting a... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090163595 - Method of modulating membrane potential of a cell: Provided herein are methods of modulating membrane potential of a cell membrane using self-assembling compounds. Also provided herein are methods of regulating a natural voltage-dependent ion channel in a cell membrane using the self-assembling compounds disclosed herein. Further provided herein are methods of treating, preventing and/or managing a disease that... Agent: Jones Day

20090163596 - Bimatoprost crystalline form i: The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of... Agent: Pearl Cohen Zedek Latzer, LLP

20090163597 - Preparation for iontophoresis: A preparation used for iontophoresis in order to absorb a physiologically active substance via the skin or mucosa using electrical driving force and the preparation containing a local anesthetic, epinephrine or its salt, water and chlorobutanol.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090163598 - Antimicrobial cellulose sponge and method of making: Biguanide bonded within a cellulose sponge inhibits or prevents the growth of microorganisms such as bacteria, mold, and fungus within the cellulose sponge over the useful life of the cellulose sponge.... Agent: 3m Innovative Properties Company

20090163599 - Mif adsorbant: The present invention concerns an apheresis material or adsorbant and a method for removing, depleting or inactivating MIF (macrophage migration inhibitory factor) from blood, blood plasma, blood serum or other body fluids. The present invention is also concerned with the use of said apheresis material or adsorbant. In order to... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090163600 - Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same: An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof.... Agent: Licata & Tyrrell P.C.

20090163601 - (r)-2-methyl-(2,5-dimethylphenyl)propanol and (s)-(2-methyl-2,5-dimethylphenyl)propanol: This invention is directed to enantiomerically enriched (R)-2-methyl-(2,5-dimethylphenyl)propanol and (S)-2-methyl-(2,5-dimethylphenyl)propanol. The chiral alcohols are synthesized in enantiomerically enriched form by the reaction of 2-methyl-(2,5-dimethylphenyl)propanone using a chiral oxazaborolidine catalyst.... Agent: Foley & Lardner LLP

20090163602 - Silicone containing polymeric materials: A polymeric material with a variable modulus of elasticity is described herein. The polymeric material described herein is useful for forming implantable medical devices (e.g. ophthalmic lenses, breast implants, and body augmentation devices). In addition, medical devices formed from the polymer material can be used to controllably release a therapeutic... Agent: Abbott Medical Optics, Inc.

20090163603 - Sulfo-polymer powder and sulfo-polymer powder blends: Sulfo-polymer powder and sulfo-polymer powder blends and subsequent preparation of dispersions of the sulfopolyester powder or sulfopolyester powder blends. The powders have reduced levels of volatiles and are generally whiter in color.... Agent: Brett L. Nelson Eastman Chemical Company

20090163604 - Process for producing tablet by high-speed direct compression: A process for producing a tablet characterized by performing high-speed direct compression with a moving speed of a pestle of 800 mm/s or more while compressing a powder which contains at least 15 to 80% by mass of cellulose, an active ingredient and a lubricant and has an angle of... Agent: Staas & Halsey LLP

  
06/18/2009 > patent applications in patent subcategories. invention type

20090156458 - Assay for the detection of factors that modulate the expression of inagp: A reporter construct contains mammalian INGAP 5′-regulatory region or a fragment thereof, a minimal promoter element from mammalian INGAP or a heterologous promoter, and a reporter gene. The reporter construct can be used to screen for agents which alone or in combination up-regulate or down-regulate reporter gene expression. Alternatively, the... Agent: Darby & Darby P.C.

20090156460 - Cationic betaine precursors to zwitterionic betaines having controlled biological properties: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090156459 - Cationic-core carrier compositions for delivery of therapeutic agents, methods of making and using the same: The present invention relates to a biocompatible cationic-core carrier composition that has sustained release capability and includes a polymeric backbone, protective chains, poly-cationic moieties and optionally an anionic load molecule.... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20090156457 - Methods and means for screening for rhomboid activity: This invention relates to methods of screening for rhomboid modulating compounds using a substrate polypeptide has a core domain comprising a rhomboid cleavable TMD sequence linked to an upstream tag sequence. The core domain sequence is not susceptible to cleavage by non-rhomboid proteases so products of rhomboid dependent proteolysis products... Agent: Bozicevic, Field & Francis LLP

20090156461 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20090156462 - Use of fibrous tissue inducing proteins for hernia repair: The present disclosure relates to hernia repair and methods for stimulating growth of fascia tissue employing compositions comprising fibrous tissue inducing proteins.... Agent: Wyeth/finnegan Henderson, LLP

20090156464 - Pharmaceutical compositions and methods for insulin treatment: Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed.... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090156463 - Photokinetic delivery of biologically active substances using pulsed incoherent light: The invention relates generally to transdermal and transmembrane delivery of biologically active substances through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transdermal and transmembrane delivery of biologically active substances using... Agent: Ropes & Gray LLP

20090156465 - Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors: The present invention relates to β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia,... Agent: Ranbaxy Inc.

20090156466 - Characterization of a mekk binding site and uses thereof: The present invention provides binding motifs, binding sites, peptides, and 14-3-3/MEKK complexes. Also provided are agents reactive with same, pharmaceutical compositions, molecules, and kits comprising same, and methods of producing same. The present invention further provides isolated nucleic acids and constructs comprising same, host cells comprising the constructs, and transgenic... Agent: Mccarthy Tetrault LLP

20090156470 - Interfering rna delivery system and uses thereof: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.... Agent: Alcon

20090156469 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating waldenstrom's macroglobulinemia: Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.... Agent: Knobbe Martens Olson & Bear LLP

20090156467 - Thymic stromal lymphpoietin promoter and use therefor: A promoter comprising the isolated promoter region of the human Thymic Stromal Lymphopoietin (TSLP) gene and functional portions of the promoter region having TSLP promoter activity. The promoters are useful for identifying promoter agonists and antagonists that can be used to prevent or treat allergic conditions and autoimmune diseases.... Agent: Nikolaos C. George Jones Day

20090156468 - Use of human chorionic gonadotropin oral or injectable for metabolic syndrome treatment: To be used as a therapy for patients with one or more of the following clinical symptoms or laboratory findings: high blood pressure, diabetes type 2, reactive hyperglycemia, plasmatic hypertriglyceridemia, hypercholesterolemia and gout as part of the metabolic syndrome.... Agent: Belluscio, Daniel Oscar

20090156471 - Use of anti-amyloid agents for treating and typing pathogen infections: A method of preventing or treating a pathogen infection in a subject is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an anti amyloid agent, thereby treating or preventing the pathogen infection in the subject.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090156472 - Cyclic depsipeptides: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090156473 - Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown: The invention relates to the treatment of viral diseases with at least one proteasome inhibitor and one inhibitor of protein-folding enzymes.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090156478 - Acylated glp-1 compounds: Protracted GLP-1 compounds and therapeutic uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090156483 - Analogs of ghrelin: wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with... Agent: Alan F. Feeney, Esq. Biomeasure, Incorporated

20090156499 - Antimicrobial peptides and methods of identifying the same: Antimicrobial peptides and methods of identifying the same are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090156480 - Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein: A biodegradable nanoparticle having a T cell recognizable epitope peptide immobilized thereon or encapsulated therein of the present invention is usable as a safe and effective immunotherapeutic agent, and is useful as an immunotherapeutic agent for treating, for example, pollinosis, year-round nasal allergic disease and seasonal nasal allergic disease.... Agent: Kubovcik & Kubovcik

20090156494 - Compositions and methods comprising gastrin compounds: The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090156495 - Compositions and methods for modulating immune responses: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and... Agent: Zymogenetics, Inc. Intellectual Property Department

20090156477 - Compositions and methods for regulating inflammatory responses: This invention relates, in part, to compositions and methods for the regulation of inflammatory responses. Specifically, the invention relates, in part, to compositions of and methods for using fibroblast growth factor (FGF) proteins, proteoglycans (e.g., syndecans), agents that modulate proteoglycans and agents that affect Wnt signaling. The invention also provides... Agent: Wolf Greenfield & Sacks, P.C.

20090156476 - Dimeric or multimeric microproteins: Disclosed is a polypeptide comprising at least two microproteins, which preferably comprise an amino acid sequence having a specific binding activity to a target protein. Furthermore, disclosed are polynucleotides encoding such a polypeptide as well as pharmaceutical compositions and kits comprising said polypeptide or polynucleotide. Also disclosed herein are methods... Agent: Arent Fox LLP

20090156502 - Diphtheria toxin variant: The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein... Agent: Lisa A. Haile, J.d., Phd. Dla Piper LLP (us)

20090156482 - External preparation, method of producing the same and usage for the same: The present invention provides an external preparation and the method for produce the same, in which said external preparation comprises recombinant human growth hormone or recombinant human granulocyte macrophage-stimulating factor and pharmaceutical acceptable carriers. The present invention also relates to application and usage method in preparing medicaments for treatment of... Agent: Morrison & Foerster LLP

20090156498 - Fusion proteins for delivery of gdnf to the cns: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.... Agent: Wilson Sonsini Goodrich & Rosati

20090156475 - Gene defects and mutant alk kinase in human solid tumors: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated... Agent: Simona Levi-minzi, Ph.d. General Counsel

20090156501 - Identification of ligands by selective amplification of cells transfected with receptors: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively... Agent: Knobbe Martens Olson & Bear LLP

20090156487 - Infant nutritional compositions for preventing obesity: The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic and alpha-linolenic acid.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090156485 - Method for coupling keratin-binding polypeptides with effector molecules which support carboxylic groups or sulfonic acid groups: The invention relates to a method of producing keratin-binding effector molecules and to intermediates and end-products of the method according to the invention and to the use of the keratin-binding effector molecules produced according to the invention in dermocosmetics.... Agent: Connolly Bove Lodge & Hutz, LLP

20090156496 - Methods and compositions for treating and preventing peripheral nerve damage: Disclosed herein is a method for treating and/or preventing peripheral nerve damage in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose... Agent: David S. Resnick

20090156479 - Methods and means for controlling the endocytosis and subsequent degradation of a cell surface protein: The invention relates to the field of regulating metabolic processes, for example to regulate the presence and/or activity of a receptor at the surface of a cell. The invention provides a method for controlling the presence of a receptor at the surface of a cell comprising interfering with the interaction... Agent: Traskbritt, P.C.

20090156474 - Methods for treating obesity and obesity related diseases and disorders: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090156491 - Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit i: The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.... Agent: David S. Resnick

20090156492 - Methods of using il-1 antagonists to treat autoinflammatory disease: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is... Agent: Regeneron Pharmaceuticals, Inc

20090156500 - Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration: Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement... Agent: Morris Manning Martin LLP

20090156497 - Non-cytotoxic pap mutants: Disclosed are PAP mutants that are less toxic than wild type PAP and that exhibit depurination activity. Also disclosed are transgenic plants that produce the PAP mutants, and methods for preparing the plants. Further disclosed are bioconjugates containing the PAP mutants, pharmaceutical compositions containing the bioconjugates, and methods of administering... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090156490 - Peptides for diagnostic and therapeutic methods for celiac sprue: Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090156486 - Production of human defensins in plant cells: The present invention relates, generally, to the production of human defensins from plant cells. Heterologous DNA comprising genes encoding one or more desired human defensins are introduced into plant cells. The one or more human defensins can be recombinantly-produced in the plant cells, purified from the plant cells, and used... Agent: Arent Fox LLP

20090156489 - Promotion of axonal regeneration: The present invention concerns a method of promoting axonal regeneration. In particular, the invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with the loss, loss of function or dysfunction of nerve cells, in particular thalamic nerve cells, by administering a... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090156493 - Urocortin-iii and uses thereof: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin... Agent: Fulbright & Jaworski, L.L.P.

20090156481 - Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) in patients treated with antiplatelet therapy: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients treated with antiplatelet therapy.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090156488 - Use of neuregulin for organ preservation: The present invention provides compositions and methods for preservation, perfusion or reperfusion of an organ, such as heart, for transplantation. The compositions comprise a preservation solution and an effective amount of neuregulin. The methods comprising contacting an organ with an effective amount of neuregulin.... Agent: Jones Day

20090156484 - Use of transferrins for treating destructive inflammation of mucous membrane: Use of at least one transferrin, preferably lactoferrin, for preventing and/or treating destructive inflammation affecting mucous membranes, optionally associated with states of hypoferremia and/or anemia and/or acute and chronic infections. The destructive inflammation is caused, for example, by pathological conditions during pregnancy and by infections sustained by intracellular or adhered... Agent: Modiano & Associati

20090156503 - Cell penetrating peptides for intracellular delivery of molecules: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090156504 - Methods of treating blood cell depletion: Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of... Agent: Jones Day

20090156505 - Self-assembly and mineralization of peptide-amphiphile nanofibers: Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.... Agent: Benet Group LLC C/o Intellevate

20090156506 - Use of vegf-d in the diagnosis of lymphangioleiomyomatosis (lam) disease: Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.... Agent: Marshall, Gerstein & Borun LLP

20090156507 - Cell permeable conjugates of peptides for inhibition of protein kinases: The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a... Agent: John P. White, Esq. Cooper & Dunham LLP

20090156508 - Synthetic peptide amides and dimeric forms thereof: e

20090156509 - Tri-peptide inhibitors of serine elastases:

20090156510 - Use of notch signaling regulators for modulating osteogenesis: The present invention provides methods of treating osteoporosis and other bone disorders by inhibiting Notch signaling.... Agent: Polsinelli Shughart PC

20090156511 - Agent for enhancing antiseptic power: The present invention relates to a preservative efficacy-enhancing agent capable of allowing an antiseptic agent to exhibit a high preservative efficacy even when the antiseptic agent is used at a low concentration; a preservative efficacy-enhancing composition containing the same; and a method for enhancing a preservative efficacy of antiseptic agents.... Agent: Birch Stewart Kolasch & Birch

20090156512 - Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient: This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R1 represents a halide, nitro, substituted C1-6 alkyl, optionally substituted amino, C1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R2 represents a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090156513 - Jucara and acai fruit-based dietary supplements: The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from... Agent: Greenberg Traurig LLP (la)

20090156514 - Novel macrolactam compounds: The invention relates generally to novel macrolactams and their analogs, to processes for the preparation of these novel macrolactams, to pharmaceutical compositions comprising the novel macrolactams; and to methods of using the novel macrolactams to treat or inhibit various disorders.... Agent: Wilmerhale/boston

20090156515 - Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof: This invention provides composition comprising a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, comprising at least two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090156516 - Benzylphenyl cyclohexane derivatives and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Townsend And Townsend And Crew, LLP

20090156518 - Stable pharmaceutical composition comprising beta-lactam antibiotic and buffer: A pharmaceutical composition, comprising: at least one β-lactam antibiotic and at least one buffer component; wherein when the pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic mixed with the β-lactam antibiotic and the buffer component.... Agent: Matthias Scholl

20090156517 - Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers: A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection... Agent: Matthias Scholl

20090156536 - Aimp2-dx2 gene and sirna targeting aimp2-dx2: The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer.... Agent: Clark & Elbing LLP

20090156539 - Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Agent: Goodwin Procter LLP Patent Administrator

20090156527 - Antiviral oligonucleotides targeting viral families: Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for... Agent: Ogilvy Renault LLP

20090156520 - Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna: Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090156537 - Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases: The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic... Agent: Wyeth Patent Law Group

20090156526 - Compositions and methods for modulation of lmna expression: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are... Agent: Knobbe, Martens, Olson & Bear, LLP

20090156541 - Dbait and uses thereof: The invention discloses the use of these molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumor cell nuclei in order to neutralize transiently their... Agent: Nixon & Vanderhye, PC

20090156534 - Globin lentiviral vectors for treatment of disease: The invention provides compositions and methods for the treatment or prevention of disease, including, for example, β-thalassemia, anemias (e.g., sickle cell anemia) and other hemoglobinopathologies.... Agent: Edwards Angell Palmer & Dodge, LLP

20090156521 - Gpr17 modulators,method of screening and uses thereof: The invention provides GPR17 modulators, methods of screening and use thereof for diagnosis and therapy of diseases or dysfunctions involving GPR17 activation, particularly ischemic brain damage.... Agent: Young & Thompson

20090156525 - Low-density lipoprotein receptor-related protein 2 clears amyloid-beta peptide a cross the blood-brain barrier via apolipoprotein j: Low-density lipoprotein receptor-related protein 2 (LRP2) is a potential receptor to regulate the level of apolipoprotein J (apoJ) in the central nervous system, which is the major carrier of amyloid-β peptide (Aβ). ApoJ is cleared from brain interstitial fluid (ISF) and cerebrospinal fluid (CSF) by LRP2-mediated transcytosis across epithelial and... Agent: Nixon & Vanderhye, PC

20090156542 - Mcp-1 binding nucleic acids and use thereof: The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney... Agent: Mdip LLC

20090156540 - Method for diagnosing and/or predicting the development of an allergic disorder and agents for treating and/or preventing same: The present invention relates to genes whose level of expression is different in allergic animals compared with non-allergic animals. In particular, the present invention relates to a method for predicting the development of an allergic disorder in a mammal by determining the gene expression pattern of a panel of specific... Agent: Stites & Harbison PLLC

20090156523 - Methods and compositions for modulating foxo1 activity and insulin signaling: The invention provides methods for modulating insulin signaling pathway and methods for treating insulin resistance. The methods employ agents which modulate FOXO1 subcellular localization. The invention also provides methods of screening for compounds that modulate insulin signaling related activities such as gluconeogenesis and cell proliferation.... Agent: Genomics Institute Of The Novartis Research Foundation

20090156543 - Methods and compositions relating to expression factors: The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090156535 - Micrornas for modulating herpes virus gene expression: An algorithm for identification of microRNA (miRNA) targets within viral and cellular RNA is disclosed. Also disclosed are essential herpes virus genes whose transcripts contain one or more targets of miRNAs encoded by herpes viruses or by host cells as predicted by the algorithm, and the use of such targets,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090156519 - Modified ksa and uses thereof: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of... Agent: Patrick J. Halloran, Ph.d., J.d

20090156538 - Modulation of endothelial lipase expression: Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090156530 - Norepinepherine transporter mutants and uses thereof: The present invention provides norepinepherine transporter (NET) mutants which display altered phosphorylation at site T30 and altered receptor trafficking. Methods for the use of the NET mutants, e.g., screening of compounds which alter NET trafficking, are also provided. A transgenic animal such as a mouse may comprise a NET mutant... Agent: Fulbright & Jaworski L.L.P.

20090156524 - Novel sirnas and methods of use thereof: The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or... Agent: Cooper & Dunham, LLP

20090156522 - Pancreatic cancer genes: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090156528 - Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering... Agent: Sirna Therapeutics, Inc.

20090156533 - Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and... Agent: Sirna Therapeutics, Inc.

20090156529 - Rnai inhibition of alpha-enac expression: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090156532 - Snp binding site for micrornas in hla-g: Analysis of microRNA interference with HLA-G expression identified the HLA-G 3′UTR SNP+3142G/C that disrupts a target for microRNA 148 (miR148) and is associated with asthma. The polymorphism is associated with protection from (or susceptibility to) moderate to severe viral infection in the first 3 years of life and asthma by... Agent: Barnes & Thornburg LLP

20090156531 - Use of inhibitors of scinderin and/or ephrin-a1 for treating tumors: The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.... Agent: Morgan Lewis & Bockius LLP

20090156544 - A1 adenosine receptor agonists: e

20090156546 - Compositions and methods for modulating the immune system: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090156545 - Substituted phosphate esters of nucleoside phosphonates: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the phosphonate nucleoside of interest to alkyloxyalkyl-phosphate or alkyl-phosphate in a phosphate-phosphono anhydride linkage to provide a modified nucleoside... Agent: Jones Day

20090156547 - Amide prodrug of gemcitabine, compositions and use thereof: The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using.... Agent: Eli Lilly & Company

20090156548 - Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer: The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient.... Agent: Fulbright & Jaworski L.L.P.

20090156550 - Composition containing oligosaccharides for the treatment/prevention of infections: The present invention relates to the use of oligosaccharide mixtures for the treatment and/or prevention of infections, in particular for reducing the severity of childhood infection or the treatment and/or prevention of childhood infection.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090156549 - Mucosal treatment: The invention provides a method of treatment of a female human or non-human subject to enhance cervical mucus penetrability by spermatozoa, which method comprises vaginally applying to said subject an effective amount of a spermicide-free, physiologically tolerable oligouronate.... Agent: Knobbe Martens Olson & Bear LLP

20090156551 - Novel composition: The invention relates to novel compositions comprising magnolol and honokiol wherein the mol ratio of magnolol to honokiol is less than 0.6 as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent: Nixon & Vanderhye, PC

20090156554 - P13-kinases: e

20090156553 - Piperazine compounds with a herbicidal action: The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.... Agent: Connolly Bove Lodge & Hutz, LLP

20090156552 - Topical delivery of phthalocyanines: The invention relates to topical pharmaceutical compositions comprising a phthalocyanine, wherein a diamagnetic metal ion moiety is either coordinated or covalently bound to the phthalocyanine core. The invention also relates to methods for destroying cancer tissue, precancerous cells, photo-aged cells, damaged cells, or otherwise pathologic cells, or activated cells, such... Agent: John T. Wiedemann Calfee ,halter & Griswold LLP

20090156556 - Aminopropanol derivatives: e

20090156555 - Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors:

20090156557 - Kinase inhibitors:

20090156558 - Phosphonate analogs of antimetabolites: The invention is related to phosphorus substituted antimetabolites, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090156559 - 2-ethyl n,n-bis(2-chloroethyl)phosphorodiamidates: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates and their salts, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer and autoimmune diseases, alone and in combination with other therapies.... Agent: Foley & Lardner LLP

20090156560 - Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090156561 - Use of cholinesterase inhibitors in smoking cessation: A method of causing a patient to reduce or cease tobacco use that involves the administration of a cholinesterase inhibitor.... Agent: Fox Rothschild LLP

20090156562 - Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts: The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may... Agent: Banner & Witcoff, Ltd.

20090156563 - Glucan compositions: A cosmetic or pharmaceutical composition is provided comprising: a) 0.001 to less than 0.2% by weight, based on the weight of the total composition, of a scleroglucan having a mean molecular weight of 1×106 to 12×106; b) a cosmetically or pharmaceutically acceptable carrier; and, optionally, c) lactic acid, a lactate... Agent: Joann Villamizar Ciba Corporation/patent Department

20090156564 - Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels: Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a... Agent: Millen, White, Zelano & Branigan, P.C.

20090156565 - Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug: A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition includes a glucocorticoid receptor antagonist and an antiepileptic drug, wherein the glucocorticoid receptor antagonist is present in... Agent: Ratnerprestia

20090156566 - Method of treating middle ear infections: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.... Agent: Alcon

20090156567 - Novel anti-inflammatory androstane derivative: u

20090156568 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090156569 - Oral contraceptive spray: The subject invention provides a liquid contraceptive formulation for oral transmucosal administration. The formulation comprises etonogestrel, optionally together with ethinyl estradiol but does not contain a matrix former or a percutaneous absorption promoter, which is a hydroxy acid or a salt thereof.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090156570 - Synergistic biocide composition comprising 2-methylisothiazoline-3-one: A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient.... Agent: Hedman & Costigan P.C.

20090156572 - Nitrogen-containing heterocyclic compound and use thereof: is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090156575 - Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases:

20090156576 - Azetidines as mek inhibitors for the treatment of proliferative diseases: Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090156574 - 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof: s

20090156571 - Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes,... Agent: Eli Lilly & Company

20090156573 - N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof: e

20090156577 - 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones:

20090156578 - 3-heterocyclylacrylamide compounds as fab i inhibitors and antibacterial agents: In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with... Agent: Goodwin Procter LLP Patent Administrator

20090156579 - Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension: The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the... Agent: Merck And Co., Inc

20090156580 - Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep: Disclosed is an anti-foot-and-mouth disease virus agent for an animal belonging to the Family Suidae, which comprises 3-oxo-3,4-dihyro-2-pyrazincarboxamide or a salt thereof. The agent is extremely useful for the prevention or treatment of food-and-mouth disease in an animal belonging to the Family Suidae. Also disclosed is an anti-foot-and-mouth disease virus... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090156581 - Aminergic pharmaceutical compositions and methods: Pharmaceutical compositions and method using aminergic compounds and complement compounds. Compositions are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound or of an adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Methods are also provided comprising the administration of: (a) a low... Agent: Harness, Dickey & Pierce, P.L.C

20090156582 - Pyrazole compound: wherein ring A0 is a pyrazole ring optionally further having 1 or 2 substituents; Ra is a substituted carbamoyl group; and Rb is an optionally substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of GSK-3β related... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090156583 - Tricyclic amide derivatives: e

20090156584 - Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam: A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090156585 - Organic compounds: A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension.... Agent: Novartis Corporate Intellectual Property

20090156586 - Compounds for the treatment of inflammatory disorders: s

20090156587 - Eye medication formulation with antibacterial agent: A formulation for administration to the eye has at least one pharmaceutical agent such as a mydriatic agent, a cycloplegic agent, an anesthetic or a non-steroidal anti-inflammation agent combined with an anti-bacterial agent and a suitable carrier. The formulation can be made for topical or intracameral administration to the eye.... Agent: Law Offices Of Jerry A. Schulman

20090156589 - 1,2-di(cyclic group)substituted benzene derivative: wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH... Agent: Birch Stewart Kolasch & Birch

20090156588 - 3,4-dihydro-benzo[e][1,3]oxazin-2-ones: The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C1-8)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-4)alkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.... Agent: Novartis Corporate Intellectual Property

20090156590 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions: e

20090156591 - Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating... Agent: Merck And Co., Inc

20090156592 - Fungicidal azocyclic amides: e

20090156593 - Spirocyclic azaindole derivatives: The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20090156594 - Heterocyclic kinase modulators: The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090156599 - Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1: Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.... Agent: Philip S. Johnson Johnson & Johnson

20090156598 - Imidazolopyrimidine modulators of trpv1: Certain TRPV1-modulating imidazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.... Agent: Philip S. Johnson Johnson & Johnson

20090156597 - Novel compounds: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090156595 - Pteridines useful as hcv inhibitors and methods for the preparation thereof: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes... Agent: Philip S. Johnson Johnson & Johnson

20090156596 - Unsaturated heterocyclic derivatives: e

20090156600 - Quinolines and their therapeutic use: Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component; in which: R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6alkyl, C1-C6-fluoroalkyl, cyclopropyl, halo, —S(O)nR6, —SO2NR7R8, —NR7R8, —NR7C(O)R6, —CO2R7, —C(O)NR7R8, —C(O)R76, —NO2, —CN or a group —OR9; wherein each R6 is independently... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090156601 - Pyrimidine derivatives for the treatment of cancer: The invention provides compounds which are pyrimidines of formula (I): wherein —XR3 is bonded at ring position 2 and —YR4 is bonded at ring position 5 or 6; R1 and R2 form, together with the N atom to which they are attached, a morphorine ring which is unsubstituted or substituted;... Agent: Viksnins Harris & Padys Pllp

20090156602 - Organic compounds: e

20090156603 - 2-aminopyridine analogs as glucokinase activators: Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating... Agent: Viksnins Harris & Padys Pllp

20090156604 - Fused bicyclic imidazoles: o

20090156605 - Quinolones and azaquinolones that inhbit prolyl hydroxylase:

20090156606 - Optical correction: The present disclosure describes compositions which improve visual acuity and to methods for their use.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090156607 - 2-oxo-1-pyrrolidine derivatives: The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090156608 - Pyridazine compound and use thereof: e

20090156609 - Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds: Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder.... Agent: Sheldon Mak Rose & Anderson PC

20090156610 - Spiroindolinone derivatives: t

20090156612 - Substituted imidazole compound and use thereof:

20090156613 - Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor: Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma,... Agent: Philip S. Johnson Johnson & Johnson

20090156611 - Mammalian hedgehog signaling modulators: The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway.... Agent: Marshall, Gerstein & Borun LLP

20090156614 - Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof: This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.... Agent: Pearl Cohen Zedek Latzer, LLP

20090156615 - Organic compounds: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent: Novartis Corporate Intellectual Property

20090156616 - Therapeutic agents: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20090156617 - Tyrosine kinase inhibitors: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090156618 - 1-(1- (2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino) - 1h-pyrazolo [4,3-d] pyrimidin-5-yl) piperidine-4-carboxylic acid and salts thereof: The present invention comprises 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical compositions, methods of treatment, and synthetic methods relating to 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts.... Agent: Pfizer Inc.

20090156619 - Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors: The present invention related to compounds of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Compounds of the present invention are useful for treating or preventing... Agent: Merck And Co., Inc

20090156620 - [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto: and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing... Agent: Townsend And Townsend And Crew, LLP

20090156622 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20090156621 - Hcv inhibitors: The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090156623 - N-aryl piperidine substituted biphenylcarboxamides: e

20090156625 - novel use of a nicotinic receptor agonist 156: The invention relates to a novel method of treatment or prophylaxis of osteoarthritis, which comprises administering to a patient in need thereof a therapeutically effective amount of an alpha 7 nicotinic AcetylCholine receptor agonist of Formula (I), or a pharmaceutically acceptable salt thereof:... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090156624 - Methionine aminopeptidase-2 inhibitors and methods of use thereof: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090156626 - Process for preparing spirocyclic cyclohexane compounds and methods of using such compounds: e

20090156628 - Aminothiazoles and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090156627 - Therapeutic compounds: e

20090156629 - Indenoisoquinoline-releasable polymer conjugates: The present invention provides releasably-linked indenoisoquinoline polymer conjugates. Methods of making the conjugates and methods of treating mammals using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090156630 - Anti-tumour polycyclic carboxamides: e

20090156631 - Controlled release compositions containing zolpidem: The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090156632 - Dosage regimen for prasugrel: A dosage regimen for treating vascular disease in a human comprising the steps of administering a loading dosage of about 30 mg to 70 mg of loading dose of prasugrel or a pharmaceutically acceptable salt thereof, and thereafter administering a daily dosage regimen of about 7.5 mg to 15 mg... Agent: Eli Lilly & Company

20090156633 - Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity: d

20090156634 - Tropane alkaloids and trigonelline combinations and methods for administering the same: A nutritional composition comprising at least an effective amount of trigonelline or derivative of trigonelline and an effective amount of tropane alkaloids, wherein the ingredients act substantially simultaneously improve the consistency of muscular contractions with respect to applied force and relaxation cycles over time and reduce the onset of central... Agent: Torys LLP

20090156635 - Biaryloxymethylarenecarboxylic acids as glycogen synthase activators: n

20090156636 - Therapeutic agent for glomerular disease: The present invention relates to a preventive and/or therapeutic agent for a glomerular disease containing, as active ingredients pitavastatin or a salt thereof and candesartan cilexetil or a salt thereof. The agent of the present invention exhibits an excellent effect in the prevention and/or therapy of a glomerular disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090156637 - Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress: The present invention includes compositions and methods for the protection of one or more central nervous system cells from trauma, when administered before, during or after the trauma, wherein the composition includes an effective amount of a butyrophenone, e.g., a 1-linked phenyl butyrophenone that is electronegative along the butyl chain... Agent: Chalker Flores, LLP

20090156638 - Uses of nordihydroguaiaretic acid (ndga) and derivatives thereof in preventing transmission of sexually transmitted diseases: Provided herein are methods for inhibiting proliferation of a microbe associated with a sexually transmitted disease (STD) or infection and for preventing transmission of one or more sexually transmitted diseases in a subject at-risk for acquiring the same, including an HIV positive subject at risk for acquiring another sexually transmitted... Agent: Benjamin Aaron Adler Adler & Associates

20090156639 - Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors: The present invention relates to composition comprising at least one L-type calcium channel blocker, particularly the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, in combination with at least one cholinesterase inhibitor, particularly donepezil, and uses thereof in methods of treatment.... Agent: Darby & Darby P.C.

20090156640 - Nociceptin analogs: e

20090156641 - Inhibition of cyclooxygenase-2 activity: The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.... Agent: Jones Day

20090156642 - 5-membered heterocyclic compound: e

20090156643 - Substituted isoxazoline compound and pesticide: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., L is —CH2—, —C(CH3)—, —CH(CN)—, etc., X is halogen atom, C1-C6haloalkyl, etc., Y is halogen atom, C1-C6alkyl, etc., R1 is —C(O)R1a, —C(O)OR1a, —C(O)NHR1a, etc., R2 is hydrogen atom, C1-C6haloalkyl, —C1-C4alkoxy... Agent: Oliff & Berridge, PLC

20090156644 - Use of thiazole derivatives and analogues in the treatment of cancer: There is provided a use of a compound of formula (I), wherein X, Y, T, W, A1, A2R1, R5 and R6 have meanings given in the description for the manufacture of a medicament for the treatment of cancer.... Agent: Morgan Lewis & Bockius LLP

20090156645 - Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors: The present invention provides methods and compositions for increasing the susceptibility of PDF inhibitors against Gram-negative organisms by using efflux pump inhibitors.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090156646 - Pyridylphenol compound and use thereof: or a salt thereof, a prodrug thereof, and a pharmaceutical agent containing the same; wherein Ring A represents a 5- to 8-membered homocyclic or heterocyclic group optionally having a substituent other than formula —X-R1 wherein X represents a bond or a spacer, and R1 represents optionally substituted amino or an... Agent: Edwards Angell Palmer & Dodge LLP

20090156647 - Method for maintaining physiological ph levels during intensive physical exercise: A nutritional supplement comprising at least a therapeutically effective amount of pyridoxine α-hydroxyisocaproate is provided by the present invention. The ingredients of the present nutritional supplement act substantially simultaneously to maintain physiological blood and muscular pH and increase the time to muscular fatigue in a mammal during periods of repetitive... Agent: Torys LLP

20090156648 - Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (hica): The present invention relates to stable salts of pyridoxine and α-hydroxyisocaproic acid (HICA) endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided.... Agent: Torys LLP

20090156649 - Cellular phosphorylation potential enhancing compositions preparation and use thereof: A pharmaceutical composition comprising as an active phosphorylation potential enhancing substance a pharmaceutically-acceptable salt of an alpha-keto carboxylic acid thereof alone or in combination with nicatinamide and creatine and, its use and products containing the same.... Agent: Werten F. W. Bellamy

20090156650 - Composition that comprises at least one oxime and its use in therapeutics: This invention relates to a medication, a pharmaceutical composition. and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).... Agent: Young & Thompson

20090156651 - Heterocyclylethylbenzamide derivatives: i

20090156652 - Therapeutic agent for food competence disorder in stomach:

20090156653 - Amino alcohol derivatives, salts thereof and immunosuppresive agents: An amino alcohol derivative represented by the following general formula (1) (for example, (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentane-1-ol) exhibits strong immunosuppressive effect while causing less side effects:... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090156654 - Derivative n-thiolated 2-oxazolidinone antibiotics: This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties against Staphylococcus spp., including methicillin resistant Staphylococcus aureus... Agent: Smith Hopen, Pa

20090156655 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20090156656 - Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity: In a process for treating disorders, especially inflammatory disorders, in the oral cavity, by introducing a substance activable by a light source, the substance comprises the active ingredient indocyanine green and the spectrum of the light source emits significant proportions in the range of 700-1000 nm.... Agent: Bachman & Lapointe, P.C.

20090156657 - Anti-inflammatory composition: The present invention provides a method of improving or preventing various conditions through suppression of the expression of inflammatory cytokines based on the action mechanism of suppression of NF-κB activation. The present invention provides a composition for suppressing NF-κB activation, containing a serotonin derivative such as feruloyl serotonin (N-feruloyl serotonin)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090156658 - Antioxidant-containing food composition for use in inhibiting histamine pathways in companion animals: The invention encompasses compositions for inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. The compositions of the invention include an amount of lipoic acid that is effective in inhibiting histamine release pathways in a companion animal, for... Agent: Colgate-palmolive Company

20090156660 - Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof: A pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution for administration to patients, containing a concentrate consisting of a pharmaceutically effective amount of docetaxel, a suitable solvent, which is preferably ethanol, a surfactant, which is polysorbate 80 and a pharmaceutically effective amount of an... Agent: Notaro & Michalos P.C.

20090156659 - System and method for collecting, storing, processing, transmitting and presenting very low amplitude signals: A method and apparatus for producing an effect of a chemical or biochemical agent on a system responsive to such agent, are disclosed. In practicing the method, a plurality of low-frequency time-domain signals of the agent are generated, each at a different at a different noise level within a selected... Agent: King & Spalding LLP

20090156661 - Compositions and methods for treatment and prevention of metabolic syndrome and its associated conditions with combinations of flavonoids, liminoids and tocotrienols: The present invention is directed to compositions and methods for the treatment and/or prevention of metabolic syndrome and its associated conditions, such as insulin resistance, which involve using a combination composition of limonoids, flavonoids and tocotrienols.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090156662 - Fat absorption inhibitor: Disclosed is a composition or beverage/food for inhibiting the fat absorption, which is derived from a natural material and therefore is safe, and which can be ingested continuously. The composition or beverage/food comprises the following components: (A) theaflavine monogallate; (B) theaflavine; (C) theaflavine digallate; and (D) polyphenol, wherein these components... Agent: Foley And Lardner LLP Suite 500

20090156665 - Compositions comprising flavonoids and toctrienols and methods thereof: Disclosed in certain embodiments is a pharmaceutical formulation comprising a pharmaceutical ingredient comprising an active agent combination comprising flavonoids and tocotrienols in a ratio of about 75:25 to about 95:5 and at least one pharmaceutically acceptable excipient.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090156663 - Functional foods comprising flavonoids and tocotrienols and methods thereof: Disclosed in certain embodiments is a functional food comprising an active agent combination comprising flavonoids and tocotrienols.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090156664 - Natural vitamin e compositions with superior antioxidant potency: Compositions for increased antioxidant potency of natural vitamin E (d-alpha-tocopherol), comprising alpha-, beta-, delta-, and gamma-forms of tocopherols and tocotrienols are disclosed. All of these compositions provide 400 International Units (IU), based on one mg of d-alpha-tocopherol provides 1.49 IU. These compositions showed antioxidant activities superior to natural d-alpha-tocopherol. These... Agent: Scott D. Rothenberger, Esq. Dorsey & Whitney LLP

20090156666 - Novel compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders: The present invention relates to novel compositions comprising magnolol and/or honokiol and glucosamine as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent: Nixon & Vanderhye, PC

20090156667 - Method of treating asthma, allergic rhinitis, and skin disorders: The use of 5,6,7-trihydroxyheptanoic acid and analogs is disclosed for the treatment of asthma, allergic rhinitis, and skin disorders such as allergic dermatitis, contact hypersensitivity, urticaria (hives), rosacea, or psoriasis.... Agent: Alcon

20090156669 - Combination of active ingredients with insecticidal and acaricidal properties: The novel active compound combination of spiromesifen and gamma-cyhalothrin has very good insecticidal and acaricidal properties.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090156668 - Ginkgolide compounds, compositions, and extracts, and uses thereof: The present invention relates to Ginkgolide derivatives, compositions and extracts comprising one or more Ginkgolides and/or derivatives thereof and methods of use of the compositions to treat neurological disorders and as imaging agents.... Agent: Wilmerhale/columbia University

20090156670 - Nonaqueous liquid parenteral aceclofenac formulation: A nonaqueous liquid parenterally deliverable pharmaceutical formulation, and more particularly a nonaqueous liquid parenteral Aceclofenac formulation comprising the selective NSAID Aceclofenac, is disclosed. A process of preparing Aceclofenac formulation, the therapeutic dosage form and storage of dose, and the method of treating a subject having a condition or a disorder... Agent: Laura A. Chub Amin Hallian, LLC

20090156671 - Deuterium-enriched oxybutynin: The present application describes deuterium-enriched oxybutynin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090156672 - Substituted phenyl aziridine precursor analogs as modulators of steroid receptor activities: Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090156673 - Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers: (Neuro)protectin D1 (1OR,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) and 15,16-dehydro-PD1 and their derivatives are useful in the treatment of airway inflammation, especially asthma.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090156674 - Valnemulin salts with organic acids: The invention relates to the production of a new salt form of valnemulin, a compound of formula I, which is notable for its good crystallinity in higher purity, its simpler technical usability and improved storage stability.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090156675 - Composition for preventing the occurrence of cardiovascular event in multiple risk patient: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring... Agent: Birch Stewart Kolasch & Birch

20090156677 - Gabapentin-containing solid compositions and process for preparing the same: The present invention provides a stabilized solid composition containing a 4-amino 3-substituted-butanoic acid derivative which can be obtained by incorporating a humectant as a stabilizer.... Agent: Pfizer Inc.

20090156679 - Levodopa prodrug mesylate, compositions thereof, and uses thereof: (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090156676 - Organic salts of beta-alanine: The present invention relates to stable salts of β-alanine and an organic acid endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided.... Agent: Torys LLP

20090156678 - Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides: e

20090156680 - Deodorants containing aminoacid derivatives: A deodorant composition comprising an aminoacid compound of formula I or II and a carrier material. I R1R2N—X—O—CH═CH—CH(NH2)CO2H II R1R2N—X—O—CH2CH2—CH(NH2)CO2H where X is an optionally substituted alkylene group comprising two carbons and R1 and R2 are independently H or CH3.... Agent: Unilever Patent Group

20090156681 - Compounds for the treatment of metabolic disorders: A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two... Agent: Wellstat Management Company. LLC

20090156682 - N-(1-methyl-2phenylethyl)benzamide derivatives: i

20090156683 - Fast release solid formulation, preparation and use thereof: The present invention relates to a chemically stable formulation of florfenicol, (and structurally related compounds) in compositions such as soluble blended powders, granules, fast-dissolving tablets or pellets suitable for rapid release of the drug in water, and to methods and kits for treating animals with aqueous compositions including florfenicol.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090156684 - Liquid antibacterial compositions incorporating trichlorocarbanilide with reduced water activity: A liquid antibacterial soap comprising trichlorocarbanilide, wherein the composition includes, 0.1-5 wt. % trichlorocarbanilide, 0-40 wt. % water, 0.1-40 wt. % of a surfactant or mixture of surfactants, 10-60 wt. % of lower glycols to render the composition visually clear and stable, and 0.1-10 wt. % of a mixture of... Agent: Snell & Wilmer, LLP (dial Corp)

20090156685 - (r)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted... Agent: Pfizer Inc.

20090156686 - Composition containing higher fatty acid derivative and foods and drinks: The composition containing a higher fatty acid derivative comprises one kind of higher fatty acid derivatives as an active ingredient and is used as an agent for prevention and treatment of osteoporosis. The higher fatty acid derivatives include octacosanal. The foods and drinks comprise the composition with a higher fatty... Agent: Kratz, Quintos & Hanson, LLP

20090156687 - Fab i and inhibition of apicomplexan parasites: Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases.... Agent: Ms. Elizabeth Arwine, Esq. Usmrmc-osja

20090156688 - Suppressant of toxicity induced by cancer chemotherapeutic agent and composition of cancer chemotherapeutic agent containing the same: Disclosed are a suppressant of toxicity such as hepatotoxicity and nephrotoxicity, induced by cancer chemotherapeutic agent, and a composition of cancer chemotherapeutic agent containing the suppressant. The suppressant of toxicity induced by a cancer chemotherapeutic agent contains xanthorrhizol as an active ingredient. Xanthorrhizol shows an excellent ability in suppressing ill... Agent: Edwards Angell Palmer & Dodge LLP

20090156689 - Method of enhancing biological activity of plant extracts: The present invention relates to a method of modulating a selected biological activity of a naturally occurring material having one or more biological activities in an extract of the naturally occurring material, the method comprising incubating the extract in a medium in the presence of an aerobically metabolizing microorganism, under... Agent: The Estee Lauder Cos, Inc

20090156690 - Deodorizing exfoliator: Disclosed is a method of treating body odor by scrubbing onto the skin a mixture of salt, one or more humectants, and one or more essential oils, with the salt being a gritty solid component in suspension within the other components so that the mixture is a viscously heterogeneous composition,... Agent: Ken Campbell

20090156691 - Cell culture carrier implantable in vivo: A cell cultivation carrier implantable in vivo having independent pore with opening of 100 μm-1000 μm on the surface thereof produced by neutralization•gellation of collagen acidic solution, said collagen acidic solution is preliminary prepared by passing through a filter of 10 μm or less pore size by 5-20 mg/mL concentration.... Agent: Hahn & Voight PLLC

20090156692 - Use of oligomers and polymers for drug solubilization, stabilization, and delivery: The invention relates to the use of oilgomers and polymers capable of rendering insoluble drugs soluble, protecting unstable drugs, and facilitating the delivery of drugs to their site of action. This invention further relates to processes for the preparation of such oilgomers and polymers, and to compositions containing them.... Agent: Nutter Mcclennen & Fish LLP

20090156693 - Ophthalmic compositions containing polysaccharide/borate gelling system: Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling... Agent: Alcon

20090156694 - Long-chain polyunsaturated fatty acid oil and compositions and preparation process for the same: Stable oil containing long-chain polyunsaturated essential fatty acids (LC-PUFAs) in the form of triacylglycerols, in particular arachidonic acid (ARA), dihomogammalinolenic acid (DHGLA), docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA). Such an oil may be prepared by bringing a carrier oil into contact with a biomass obtained from the culture of... Agent: K&l Gates LLP

  
06/11/2009 > patent applications in patent subcategories. invention type

20090149371 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations... Agent: Philip S. Johnson Johnson & Johnson

20090149372 - Bmp10 propeptides and related methods: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.... Agent: Ropes & Gray LLP

20090149383 - Compositions and methods for facilitating heme-iron export from cells: The invention provides a high affinity heme-binding agent, which can be provided in the form of a pharmaceutical composition that includes, optionally, a pharmaceutically acceptable carrier. The heme-binding agent can be used in a method of facilitating heme-iron export from a cell. The method comprises contacting a cell with a... Agent: Karen S. Canady Canady & Lortz LLP

20090149388 - Dried blood factor composition comprising trehalose: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.... Agent: Morrison & Foerster LLP

20090149378 - Glp-1 analogues: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.... Agent: Biomeasure, Incorporated

20090149377 - Methods for regulation of p53 translation and function: The present invention relates to novel methods for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. More specifically, the invention relates to novel methods for modulating p53 mRNA translation in a cell by affecting a function of a p53 5′-untranslated region (5′UTR), including its interaction... Agent: St. Jude Children''s Research Hospital C/o Darby & Darby P.C.

20090149381 - Methods of regulating angiogenesis through stabilization of pedf: The invention provides methods of inhibiting angiogenesis within a tissue, promoting neuron protection within a tissue, and treating a disease in a mammal, wherein (a) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof or (b) a protein of a serpin... Agent: Leydig Voit & Mayer, Ltd

20090149382 - Modulation of lipid rafts: The present invention relates to the use of an antisecretory protein, derivative, homologue, and/or fragment thereof, having equivalent activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of dysfunction, e.g. abnormal function, hypo- or hyper-function of... Agent: Bingham Mccutchen LLP

20090149385 - Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration: Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement... Agent: Morris Manning Martin LLP

20090149386 - Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration: Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement... Agent: Morris Manning Martin LLP

20090149374 - Neuropeptides: The present invention describes a polypeptide, comprising the amino acid sequence APAHRSSTFPKWVTKTERGRQPLRS (Seq. ID. No. 1) or a fragment thereof, said fragment comprising at least 7 consecutive amino acid residues of Seq. ID. No. 1.... Agent: Chalker Flores, LLP

20090149379 - Novel use of cytokine inhibitors: The present invention relates to a method for prevention or reduction of scar tissue and/or adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.... Agent: Buchanan, Ingersoll & Rooney PC

20090149376 - Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase polymorphism in asthma and reversible bronchial obstruction: A pharmaceutical composition comprising an expression product of a Type Nine adenylyl cyclase gene polymorphism, along with a suitable physiological carrier, are provided. In addition, methods related to treating patients having asthma or a reversible bronchial obstruction, kits for determining the responsiveness of an individual to treatment regimens, and assays... Agent: Dinsmore & Shohl, LLP

20090149384 - Protection of photoreceptors in experimental autoimmune uveitis: Techniques are described for the administration of crystallins, e.g., αA and/or β crystallin, to protect retinal photoreceptors of subjects inoculated with Experimental Autoimmune Uveitis. The present disclosure provides a unique and novel approach to the prevention of photoreceptor degeneration in uveitis and other blinding diseases mediated by oxidative stress including... Agent: Mcdermott Will & Emery LLP

20090149387 - Use of glp-1 peptides: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090149373 - Use of survivin to treat kidney failure: The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of... Agent: Nixon & Vanderhye, PC

20090149375 - Use of the mst protein for the treatment of a thromboembolic disorder: The present invention refers to the use of the Mst protein or a nucleotide sequence coding for the Mst protein for the treatment of a thromboembolic disorder and to a method of screening a modulator of the Mst protein or the nucleotide sequence coding for the Mst protein.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090149380 - Vasostatin as marrow protectant: Specific fragments of vasostatin are disclosed. These fragments are of use in methods of stimulating the proliferation or survival of a hematopoietic cell exposed to a chemotherapeutic agent or irradiation. Methods of stimulating the proliferation or survival of a hematopoietic cell using these fragments are also disclosed. In one embodiment,... Agent: Klarquist Sparkman, LLP

20090149389 - Kinase inhibitors and uses thereof: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20090149391 - Novel antimicrobial bolisin peptides: The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics,... Agent: Jacobson Holman PLLC

20090149390 - Oxidant resistant apolipoprotein a-1 and mimetic peptides: A purified polypeptide includes an ApoA1 mimetic or fragment thereof that are resistant to oxidation.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090149392 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090149393 - Novel proteins within the type e botulinum neurotoxin complex: The invention features a polypeptide complex synthesized by bacteria of the genus Clostridia that contains the serotype E botulinum neurotoxin and five neurotoxin associated polypeptides having molecular weights of about 118, 80, 65, 40, and 18 kDa, respectively. The complex is useful in the treatment of diseases or conditions that... Agent: Fish & Richardson PC

20090149394 - Use of effectors of glutaminyl and glutamate cyclases: The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting... Agent: Sonnenschein Nath & Rosenthal LLP

20090149396 - Derivative of glucose and vitamin f, compositions comprising it, uses and preparation process: An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090149395 - Novel macrocyclic polyene lactams: The invention relates generally to novel macrocyclic polyene lactams and their analogs, to processes for the preparation of these novel macrocyclic polyene lactams, to pharmaceutical compositions comprising the novel macrocyclic polyene lactams; and to methods of using the novel macrocyclic polyene lactams to treat or inhibit various disorders.... Agent: Wilmerhale/boston

20090149397 - Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors: In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In... Agent: Wilson Sonsini Goodrich & Rosati

20090149398 - 6,11-3c-bicyclic 8a-azalide derivatives: Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2′, are described herein. The compounds exhibit antibacterial properties. The compounds of Formula (I) can be employed to treat or prevent bacterial infections as compounds per... Agent: Merck And Co., Inc

20090149399 - Heterocyclic kinase inhibitors: This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and... Agent: Edwards Angell Palmer & Dodge LLP

20090149400 - Anti-proliferative compounds, compositions, and methods of use thereof: i

20090149401 - Amide and peptide derivatives of tetraalkylenepentamines as transfection agents: This invention relates to newly identified pentamine based surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the pentamine based compounds to facilitate the transfer of polynucleotides into cells.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090149411 - Immunostimulatory oligonucleotides with modified bases and methods of use thereof: Immunomodulatory oligonucleotide compositions are disclosed. These oligonucleotides comprise an immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.... Agent: Morrison & Foerster LLP

20090149412 - Method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure: The present invention provides a method for the treatment of heart failure through the use of small peptide complexes and recombinant proteins which function to enhance contractility in failing hearts and reduce blood pressure in individuals with hypertension by inhibiting the interaction between phospholamban and sacroplasmic reticulum Ca2+ ATPase (SERCA2a)... Agent: Dla Piper LLP (us)

20090149410 - Methods, compositions, and kits relating to chitinases and chitinase-like molecules and inflammatory disease: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease,... Agent: Ropes & Gray LLP

20090149404 - Oligonucleotide analogues and methods utilizing the same: e

20090149402 - Pharmaceutical composition for treating cancer or diabetes: (B) a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase (NEU3) and contains the sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 8, and the... Agent: Knobbe Martens Olson & Bear LLP

20090149406 - Plasmid pxl3179 or nv1fgf: A prokaryotic recombinant host cell comprising a heterologous replication initiation protein that activates a conditional origin of replication and an extrachromosomal DNA molecule comprising a heterologous therapeutic gene and a conditional origin of replication whose functionality in the prokaryotic recombinant host cell requires a replication initiating protein which is foreign... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090149414 - Raav expression systems and compositions: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides,... Agent: Haynes And Boone, LLPIPSection

20090149408 - Rna interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090149407 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded... Agent: Sirna Therapeutics, Inc.

20090149413 - Rors as modifiers of the p21 pathway and methods of use: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090149403 - Sirna silencing of genes expressed in cancer: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.... Agent: Townsend And Townsend And Crew, LLP

20090149409 - Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system: A vector and a method are provided for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first... Agent: Brinks Hofer Gilson & Lione

20090149405 - Virus-like particle containing a dengue virus recombinant replicon: The present invention relates virus-like particle vaccine containing dengue virus recombinant replicon as its core and its preparation method. Such vaccine can efficiently express antigen in the infected tells. Because dengue virus can infect dendritic cells, it can efficiently present antigen and has immunity effects. Further, different dengue virus types... Agent: Mdip LLC

20090149416 - 2' and 3'-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.... Agent: Susanne Hollinger King & Spalding LLP

20090149415 - Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex: The invention relates to compounds for modulating the glycolosis enzyme complex and the transaminase complex, to pharmaceutical compositions containing said compounds, and to the uses of said compounds for the production of pharmaceutical compositions for treating different diseases.... Agent: Mayer & Williams PC

20090149417 - Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20090149418 - Antimicrobial preparations using polysaccharide gel from durian fruit-rind: A water-soluble polysaccharide gel having good gelling property and good antimicrobial activity was extracted from fruit-rind of durian (Durio zibethinus Murr.) comprises steps of boiling dried fruit rind with 25-30 volumes by weight of water, filtering, repeating boiling residue 1-2 times with 15 volume by weight of water. Filtrates were... Agent: Dr. Sunanta Pongsamart Department Of Biochemistry

20090149419 - Hydrazido derivatives of hyaluronic acid: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090149420 - Novel compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders: The present invention relates to novel compositions comprising magnolol and/or honokiol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent: Nixon & Vanderhye, PC

20090149421 - Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state: There is disclosed aqueous solutions of polyelectrolytes that can be neutralized by increasing temperature, under suitable polyelectrolyte charge state conditions, in order to obtain a homogeneous gel. This can be achieved by adding an appropriate weak electrolyte to the polyelectrolyte so that an increase of temperature will lead to a... Agent: David S. Resnick

20090149422 - Hemostatic material: A hemostatic powder comprises a chitosan salt together with at least one medical surfactant. At least one inert material may optionally be included. The hemostatic powder may be incorporated into wound dressings.... Agent: Barlow, Josephs & Holmes, Ltd.

20090149424 - Heparin conjugates and methods: Heparin conjugates and methods of making and use thereof are disclosed. An illustrative heparin conjugate includes a composition wherein a bile acid is bonded to heparin through the 3-carbon of the bile acid. A spacer may be interposed between the bile acid and the heparin. Another embodiment includes a targeting... Agent: Alan J. Howarth

20090149423 - Use for a very low molecular weight heparins: The present invention relates to the use of heparin oligosaccharides having a molecular weight≦5050 Da and an anti-factor Xa activity≦80 IU/mg, or their sodium salts, for preparing a medicament for the prevention and treatment of osteoporosis and associated pathologies and for preparing a medicament effective for the prevention and treatment... Agent: Mccormick, Paulding & Huber LLP

20090149425 - Malononitrile compound as pesticides: The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represent nitrogen or CR5, provided that 1 to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090149426 - Process for synthesizing silver-silica particles and applications: Size-controlled immobilization of metal nano-clusters onto particles or nanoparticles is achieved using a polyol process. Polyol processing makes it possible to use thiol groups as a chemical protocol to functionalize the surface of particles, such as silica and polystyrene nanoparticles. Metal nano-clusters, such as silver, gold, platinum and palladium, nucleate... Agent: Christopher Paradies, Ph.d.

20090149427 - Pharmaceutically acceptable salts and hydrates of risedronic acid: The present invention is concerned with new hydrated forms of risedronate salts, processes of preparing the new hydrated forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same. In particular, the present invention provides tri-sodium risedronate dihydrate.... Agent: Foley & Lardner LLP

20090149429 - Antiviral compounds: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090149430 - Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament: The present invention relates to a composition containing at least one amidine derivative or carboxamide derivative of general formula (I) or (A) in combination with at least one compound chosen from steroids, corticoids or corticosteroids, wherein said composition is suitable for the preparation of a medicament.... Agent: Hunton & Williams LLP Intellectual Property Department

20090149428 - Methods for assessing the predisposition or susceptibility to copd: This invention relates to novel associations between polymorphisms in the genes encoding the human Epithelial Na+ Channel (ENaC) and COPD. More particularly, the invention relates to a method for assessing the predisposition and/or susceptibility of an individual to COPD, which method comprises detecting the presence of a polymorphism in one... Agent: Fish & Richardson P.C.

20090149431 - Eplerenone drug substance having high phase purity: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a... Agent: Pfizer Inc.

20090149433 - Compositions for the treatment of inflammation of the gastrointestinal tract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090149432 - Methods for administering corticosteroid formulations: Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving... Agent: Morrison & Foerster LLP

20090149434 - Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride: Compositions comprising a polyglycolysed glyceride, such as GELUCIRE, and a steroid related compound are provided.... Agent: Howrey LLP - East

20090149435 - Process for making a pharmaceutical composition: Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate.... Agent: Allergan, Inc.

20090149436 - Caspase inhibitor: The present invention provides a caspase inhibitor containing a cobalt porphyrin complex compound or cobalt choline complex compound as an active ingredient. The caspase inhibitor of the present invention can strongly and specifically inhibit the caspase activity. In addition, the caspase inhibitor/cobalt porphyrin complex compound or cobalt choline complex compound... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090149437 - Thieno-pyridine derivatives as mek inhibitors: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.... Agent: Feldmangale, P.A.

20090149439 - Pyridylmethysulfone derivative: s

20090149438 - Pyrimidines as plk inhibitors:

20090149441 - Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics:

20090149440 - Novel pyridonecarboxylic acid derivatives or salts thereof: or a salt thereof, wherein R1 represents a methyl group, a fluorine atom, or a chlorine atom; R2 represents a hydrogen atom or a lower alkyl group; R3 represents an isopropyl group or a tert-butyl group; R4 represents a methyl group or a halogen atom; and R5 represents a fluorine... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090149442 - Atypical antipsychotic agents having low affinity for the d2 receptor:

20090149443 - P38 inhibitors and methods of use thereof: Compounds of formula (I): in which A, B, X, Ar1, R8 and R4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.... Agent: Viksnins Harris & Padys Pllp

20090149444 - Benzylamine analogues: wherein R1 represents a C1-C6 alkyl, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are the same or different and represent hydrogen or a C1-C6 alkyl; Ra represents hydrogen, C1-C6 alkyl or C2-C6 alkenyl or together with R2 represents a C1-C3 alkylene; Arom represents a heteroaryl;... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090149445 - Tricyclic steroid hormone nuclear receptor modulators: e

20090149446 - Compositions comprising nicotinic agonists and methods of using same: The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that include a nicotinic agonist (for example, nicotine) and a nicotinic acetylcholine receptor desensitization inhibitor (for example, opipramol).... Agent: Goodwin Procter LLP Patent Administrator

20090149447 - Novel m3 muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090149448 - Phenoxyacetic acid derivatives useful for treating respiratory diseases: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20090149449 - Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto: wherein X, Y, R1-R7, T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a... Agent: Leydig, Voit & Mayer, Ltd.

20090149450 - Substituted imidazoheterocycles: e

20090149451 - Pharmaceutical formulations of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel... Agent: Foley & Lardner LLP

20090149452 - Xanthine oxidase inhibitor: A compound represented by the following formula (I) is used as a xanthine oxidase inhibitor: in which R1 is phenyl or pyridyl each optionally having, as a substituent, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, carboxyl, halogeno, hydroxyl, nitro, cyano, amino, etc.; R2 is cyano, nitro, etc.; X is oxygen, sulfur,... Agent: Nixon Peabody, LLP

20090149453 - Methods and compositions for treating bacterial infections and diseases associated therewith: The invention features methods and compositions for treating bacterial infections.... Agent: Intellectual Property / Technology Law

20090149454 - Benzomorpholine derivatives and methods of use: Selected benzomorpholine compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject... Agent: Amgen Inc.

20090149456 - 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090149455 - Use of triazolopyrimidines for controlling plant diseases on legumes: e

20090149457 - 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors: There are provided thieno[2,3-c]pyrazole derivatives of formula (I), wherein A is an aryl or heteroaryl ring, on which the substituent-NHZR5 is at the ortho position to the CONH linker; R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom or an organic group;... Agent: Scully Scott Murphy & Presser, PC

20090149458 - Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors: e

20090149459 - P38 inhibitors and methods of use thereof: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.... Agent: Viksnins Harris & Padys Pllp

20090149460 - New compounds: i

20090149461 - Method of treating cancer: Methods of treating cancer using N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090149462 - Process for purification of aprepitant: The present invention relates to a process for obtaining pure aprepitant substantially free of undesired diastereomeric isomer, namely 5-[2(S)-[1(RS)-[3,5-bis(trifluoromethyl)-phenyl)ethoxy]-3-(S)-(4-fluorophenyl)-morpholin-4-yl-methyl]-3,4-dihydro-2H-1,2,4-triazol-3-one. The present invention further provides an improved process for preparation of aprepitant crystalline form II. The present invention also relates to novel amorphous form of aprepitant, a process for its preparation... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090149463 - Therapeutic agents: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20090149464 - Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases: Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.... Agent: Oliff & Berridge, PLC

20090149465 - Aminotetralin compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid... Agent: Theravance, Inc.

20090149466 - Inhibitors of stearoyl-coa desaturase: e

20090149468 - Substituted heterocyclic compounds and methods of use: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.... Agent: Amgen Inc.

20090149467 - Tyrosine kinase inhibitors: The present invention relates to pyridinyloxy- and pyrimidinyloxyindole derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer... Agent: Merck And Co., Inc

20090149469 - Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors: e

20090149470 - Novel aminopyridine derivatives having aurora a selective inhibitory action: wherein m1 and m2 are 1, 2, or 3; n1 and n2 are 0 or 1; i is an integer of any of 1 to m1; j is an integer of 1 to m2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rai and Rai′ is... Agent: Merck And Co., Inc

20090149471 - Monocyclic heterocyclic compounds: e

20090149472 - Salts of substitutted pyrazoline compounds, their preparation and use and medicaments: The present invention relates to salts of substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20090149473 - Topical antifungal composition: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content of less... Agent: The Nath Law Group

20090149474 - Gaba-b receptor modulators: The present invention relates to novel imidazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux... Agent: White & Case LLP Patent Department

20090149475 - Thioxanthine derivatives and their use as inhibitors of mpo: There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090149477 - 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments: e

20090149476 - Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same:

20090149478 - Novel combination anticancer agents: Group C: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the aryl ring may comprise one to three substituents selected from the group consisting of a hydroxy group, a C1-C6 alkoxy group, an amino group,... Agent: Foley And Lardner LLP Suite 500

20090149480 - Methods of using pde v inhibitors for the treatment of congestive heart failure: o

20090149481 - Pharmaceutical composition and beverage composition comprising l-arginine: A pharmaceutical composition and a beverage composition comprising the following three components (A), (B) and (C): (A) L-arginine or a salt thereof; (B) caffeine or a salt thereof; and (C) at least one substance selected from the group consisting of vitamin C or a derivative thereof, vitamin E or a... Agent: Hoffmann & Baron, LLP

20090149482 - Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment: Stereochemically defined dipeptide esters of nucleoside-analogous antiviral agents including acyclovir and ganciclovir are provided. Certain of these stereochemically defined dipeptide esters are found to have unexpectedly enhanced delivery to and uptake by ocular tissues, crossing the blood-ocular barrier more effectively than other stereochemically defined dipeptide esters. For example, (L-Val)-(D-Val)-acyclovir was... Agent: Schwegman, Lundberg & Woessner, P.A.

20090149479 - Dosing regimen: Methods and kits are provided enabling a twice daily dosing regimen that achieves daily patient blood levels of active pharmaceutical ingredient comparable to a dosing regimen requiring the same active ingredient to be administered three times a day.... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090149483 - Bicyclic pyrrole derivatives: t

20090149484 - Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of... Agent: Astrazeneca R&d Boston

20090149486 - 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments: e

20090149485 - Pyrimidinediones as tyrosine kinase inhibitors: or its stereoisomers, tautomers, solvates, hydrates, prodrugs, pharmaceutically acceptable salts or mixtures thereof, or pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides a method for the prophylaxis or treatment of a medical condition associated with protein kinase, by administering... Agent: Sughrue Mion, PLLC

20090149487 - 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments:

20090149488 - Tetrahydroprotoberberine compounds, the synthetic method and the use thereof: The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment... Agent: Nixon & Vanderhye, PC

20090149490 - Spermicidal and/or antifungal composition and methods of using the same: Hexahydroindenopyridine compounds are provided which act as spermicides and/or fungicides, spermicidal and/or fungicidal compositions containing the same, and methods for killing motile sperm and/or fungi using the compounds and compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090149491 - Carbocyclic oxime hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic... Agent: Elmore Patent Law Group, PC

20090149492 - 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods: i

20090149493 - Inhibitors of the interaction between mdm2 and p53: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, A and Z have defined meanings.... Agent: Philip S. Johnson Johnson & Johnson

20090149494 - Therapeutic use of imidazo[1,2-a]pyridine-2-carboxamide derivatives: e

20090149495 - Compounds: The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) wherein X represents a group selected from CO, SO, SO2; Y represents a group selected from 0, OCH2, (CH2)n, NH, NHCH2; n is an integer of 0 to 2; R1 is an optionally substituted... Agent: Fish & Richardson P.C.

20090149496 - Inhibitors of the task-1 and task-3 ion channel: The invention relates to the use of Kv1.5 inhibitors for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090149497 - Polymorphs of fexofenadine hydrochloride: The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII through XV and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of ethyl acetate, while Form IX is anhydrous, but can... Agent: Kenyon & Kenyon LLP

20090149498 - Pharmaceutical composition having prokinetic effect: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition that restores and/or enhances the activity of the neuronal nitric oxide synthase enzyme.... Agent: Birch Stewart Kolasch & Birch

20090149501 - Novel indoles are cannabinoid receptor ligands: e

20090149500 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Jones Day

20090149499 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione): Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Jones Day

20090149502 - Optically active isomers of ketotifen and therapeutically active metabolites thereof: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.... Agent: Nields, Lemack & Frame, LLC

20090149503 - New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes: c

20090149505 - Metabotropic glutamate receptor-potentiating isoindolones:

20090149504 - Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors: The present invention relates to 5-substituted indole derivatives of formula (I): having inhibitory potential of dipeptidyl peptidase IV (DPP IV) enzyme where x and R1 are defined as defined in the specification... Agent: Narinder S. Banait Fenwick & West LLP

20090149506 - Insecticidal compositions with improved effect: The present invention relates to increasing the activity of crop protection compositions comprising anthranilic acid diamides through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing them and to their use in... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090149507 - Method for customized dispensing of variable dose drug combination products for individualizing of therapies: The method set out herein involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090149508 - Process for the preparation of substituted phenyl ether compounds: A novel process for the preparation of a compound of the formula (II), which is useful as intermediate compound for the preparation of thiazolidinedione derivatives, such as rosiglitazone, pioglitazone, troglitazone and ciglitazone, is disclosed.... Agent: Sandoz Inc

20090149509 - Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use: N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090149510 - Compositions and methods for modulating a kinase cascade: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090149511 - Administration of an inhibitor of hdac and an mtor inhibitor: Methods of treating patients with an HDAC inhibitor and an mTOR inhibitor are provided.... Agent: Wilson Sonsini Goodrich & Rosati

20090149512 - Use of ghrelin antagonists to the treatment of certain cns diseases: Ghrelin antagonists can be used for the treatment of certain CNS disorders. For example, certain oxadiazoles, preferably such being ghrelin antagonists, can be used to treat obesity, e.g., drug-induced obesity.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090149513 - Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with... Agent: Jones Day

20090149514 - Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention relates to methods to use non-steroidal ligands in nuclear receptor-based inducible gene expression system to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising:... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090149515 - Treatments for the control of schistosomiasis: A method for controlling schistosome parasites in a mammal comprising delivering an effective amount of an agent for silencing TGR activity in the parasites.... Agent: Drinker Biddle & Reath LLP Attn: Patent Docket Dept.

20090149517 - Novel 2-substituted tiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals: The present invention relates to 2-substituted thiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof... Agent: Millen, White, Zelano & Branigan, P.C.

20090149516 - Synthesis of epothilones, intermediates thereto, analogues and uses thereof: e

20090149518 - Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis: The present invention relates to an agent for protecting a motor nerve of a patient with amyotrophic lateral sclerosis, which comprises a combination of (a) (2R)-2-propyloctanoic acid or a salt thereof and (b) a therapeutic agent for amyotrophic lateral sclerosis such as riluzole. An agent comprising a combination of (a)... Agent: Sughrue-265550

20090149519 - Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments: e

20090149520 - Oxazolidinones containing oxindoles as antibacterial agents: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X is C1-4alkyl; and Y is H or F. The compounds of the present invention are useful as antibacterial agents.... Agent: Pfizer Inc Steve T. Zelson

20090149521 - Dual-acting benzoimidazole antihypertensive agents: wherein Ar, r, n, X, R2, R2′, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a... Agent: Theravance, Inc.

20090149522 - Method of preserving a customised composition: The invention concerns a process for producing a preserved customised consumer composition, preferably from a Vending machine, wherein a plurality of ingredient streams are mixed together in predefined relative amounts, characterised in that At least two streams consist of water and preservative only, at least two of which having different... Agent: Unilever Patent Group

20090149523 - Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases: The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes.... Agent: Clark & Elbing LLP

20090149524 - N-(phenylmethyl)-2-(1h-pyrazol-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration: e

20090149527 - Apparatus and method for application of a pharmaceutical to a surface of an external ear canal for treatment of keratosis obutrans: A packaged kit for treating keratosis obturans includes a plurality of ear needles having different shaped absorbent applicators on distal ends of the needles, a vial of a single dose of an otologic formulation of mitomycin-C, and a diluent carrier syringe containing sterilized water. The component parts of the kit... Agent: Thompson Coburn LLP

20090149525 - Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy: The invention relates to derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, which can be used in photodynamic therapy. According to the formulas of the invention, X1, X2, X3, X4, X5, X6, X7, X8, which maybe identical or different, each represent halogen atoms or hydrogen atoms. R1, R2, R3, R4, which... Agent: Egbert Law Offices

20090149526 - Tetracyclic indole derivatives as antiviral agents: The present invention relates to tetracyclic indole derivatives of formula (I): wherein Ar, A, R1, R2, L, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20090149528 - Cinnamic acid amides: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection.... Agent: Edwards Angell Palmer & Dodge LLP

20090149529 - Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals: The invention encompasses compositions for enhancing the ability of a companion animal to resist and/or overcome viral infections. The compositions of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.... Agent: Colgate-palmolive Company

20090149530 - Antiinfective flavonol compounds and methods of use thereof: e

20090149531 - Chemical composition derived from p-hydroxyphenyl propionic acid for the treatment of psoriasis:

20090149532 - Herpesvirus-derived therapeutic agent for pain: A therapeutic agent for treatment of herpes virus-derived pain which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by the formula (1) as an active ingredient.... Agent: Kubovcik & Kubovcik

20090149533 - Novel fenofibrate formulations and related methods of treatment: The invention provides novel omega-3 ester-based oil solutions of fenofibrate. These solutions are substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the solutions of the invention contain an omega-3 ester-based oil as the major ingredient, they not only provide an antihyperlipidemic effect due... Agent: Ratnerprestia

20090149534 - Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol: Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, pharmaceutical compositions which contain these modifications, and the use thereof to treat pain or other conditions.... Agent: Crowell & Moring LLP Intellectual Property Group

20090149535 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and... Agent: Theravance, Inc.

20090149536 - 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders: A method for the treatment of dermatological disorders wherein such treatment includes at least one of inhibiting lipogenesis in the skin and reducing the size of sebaceous glands, said treatment comprising the topical administration of a compound selected from 4-oxo-tretinoin, 4-oxo-isotretinoin and mixtures thereof to a patient in need thereof.... Agent: Gibbons P.C.

20090149537 - Use of bile acid or bile salt fatty acid conjugates: in which G is a bile acid or bile salt radical, which, if desired, is conjugated in position 24 with a suitable amino acid, W stands for one or two fatty acid radicals having 14-22 carbon atoms and X stands for a suitable bonding member or for a direct C═C... Agent: Townsend And Townsend And Crew, LLP

20090149538 - Aspirin-triggered lipid mediators: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090149539 - Pet food compositions and methods: In yet another embodiment, the disclosure is directed to methods selected from promoting bone or joint health, promoting chondrocyte functioning, maintaining tissue concentration of omega-3 fatty acids, promoting tissue concentration of omega-3 fatty acids, and combinations thereof, including the like, in a pet, comprising administration of a composition comprising SDA... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090149540 - Compositions and methods for attenuating mitochondria-mediated cell injury: The present invention relates to a S-nitrosated mitochondria-targeted thiol-based antioxidant prodrug and uses therefore for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. When activated, prodrug of the present invention can specifically provide a NO* donor and a... Agent: Licata & Tyrrell P.C.

20090149541 - Method of delaying the onset of clinically definite multiple sclerosis: A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the... Agent: Cooper & Dunham, LLP

20090149542 - Compounds and compositions for treating neuronal death or neurological dysfunction: The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration... Agent: Seed Intellectual Property Law Group PLLC

20090149543 - Solid pharmaceutical compositions comprising lumiracoxib: A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions... Agent: Novartis Corporate Intellectual Property

20090149544 - Alpha-aminoamide derivatives: This invention relates to novel alpha-aminoamide derivatives, their pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of monoamine oxidase... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090149546 - Enhanced bimatoprost ophthalmic solution: i

20090149545 - Treatment of coronavirus infection: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1,... Agent: Occhiuti Rohlicek & Tsao, LLP

20090149547 - Virucidal disinfectant for avian influenza virus: m

20090149548 - Novel 1,2-diphenylethene derivatives for treatment of immune diseases: The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases.... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20090149549 - Preparation of chiral amides and amines: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides... Agent: Morgan, Lewis & Bockius LLP (sf)

20090149550 - Wrinkle reduction agent, lipolysis accelerator, composition for external use on skin, and food or beverage composition: i

20090149551 - Oxidized cis-terpenone and its use as a chemoprotective and anti-malarial agent: 4b,5,6,7,8,8a-cis-hexahydro-2-hydroxy-4b,8,8a-trimethylphenanthren-9,10-dione (OHCT) is a fully oxidized compound based on the 2-hydroxy-cis-terpenone (HCT). Because OHCT is fully oxidized, it is more stable and less likely to damage cells or cell constituents such as DNA. OHCT has antimalarial activity, noncompetitive inhibitory activity against carcinogenic conversion of aflotoxin B1 (AFB1) to exo-AFB1-epoxide thus... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090149552 - Pesticides based on vicinal diols: Pesticides based on vicinal diols, are available to control arthropod ectoparasites such as Pediculus Humanus, Dermatophagoides pteronyssinus, Musca domestica, the Blattidae, Blatella Germanica, and Periplaneta Americana, by introducing to the locus of an infestation of the pest, a composition containing as active ingredient a vicinal diol.... Agent: Jacobson Holman PLLC

20090149553 - Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects: An injectable resorbable bone graft material, and methods of using the same, provide increased compressive strength after injection in a bone defect. The bone graft material is made from calcium sulfate hemihydrate having a thick stubby rod-like crystalline structure and low water-carrying capacity.... Agent: Alston & Bird LLP

20090149554 - Water-soluble metal alcoholate derivatives, production methods thereof, and solid gelatinous external preparations containing the same: The object of the present invention is to provide a production method of water-soluble silane derivatives, the separation and purification of which are easy, and the reaction for which can be conducted under an industrially practicable temperature condition (under the temperature condition of 90° C. or lower) and to provide... Agent: Rankin, Hill & Clark LLP

20090149555 - Method for preparing polyhydroxyalkanoates, polymers thus obtained, compositions comprising them and their uses: e

20090149556 - Non-tumorigenic ointment/cream base for topical application: A non-tumorigenic skin care composition is provided.... Agent: Dann, Dorfman, Herrell & Skillman

  
06/04/2009 > patent applications in patent subcategories. invention type

20090143275 - Adiponectin receptor fragments and methods of use: Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin... Agent: Siemens Corporation Intellectual Property Department

20090143277 - Nutritional composition for controlling blood sugar level: The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090143278 - Process for preparing bioactive protein-enriched whey products: The present invention involves the discovery that various liquid (whey) streams drained or expelled from cheese curd after salt addition in the preparation of cheese contain enriched levels of bioactive proteins such as lactoferrin, lactoperoxidase, immunoglobulins, and growth factors. According to the invention, these proteins may be further enriched through... Agent: Schwegman, Lundberg & Woessner, P.A.

20090143276 - Trimeric il-1ra: Interleuekin-1 receptor antagonists (IL-1Ra) including fusion proteins having a trimerizing domain and an IL-1Ra polypeptide sequence. The fusion proteins are part of trimeric complexes that are used in pharmaceutical compositions for treating diseases mediated by IL-1. Effective treatment of inflammatory diseases, such as rheumatoid arthritis and diabetes, are described.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090143279 - Methods and compositions for treating metabolic disorders: The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in... Agent: Ropes & Gray LLP

20090143280 - Anti-cancer combination treatment and kit-of-parts: In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090143281 - Thrombomodulin analogs for use in recovery of spinal cord injury: The present invention relates to the use of thrombomodulin analogs for the treatment of trauma-induced spinal cord injury.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090143282 - Enhanced recovery following ocular surgery: An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090143298 - Broad-spectrum delta-endotoxins and method and kit for detecting same and for detecting polynucleotides encoding same: Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using these genes and proteins are disclosed as well as methods for the recombinant expression, and... Agent: Howrey LLP

20090143301 - High calorie nutritional supplement: The invention provides a nutritional supplement comprising a protein source including milk protein isolate and/or canola plant protein, as well as related methods for its production and use in treating a nutritional deficiency in an individual.... Agent: K&l Gates LLP

20090143292 - Liquid formulation of g-csf conjugate: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable... Agent: Morgan, Lewis & Bockius LLP (sf)

20090143286 - Methods and compositions for regenerating articular cartilage: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.... Agent: Leon R. Yankwich Yankwich & Associates, P.C.

20090143296 - Methods and compositions for the repair and/or regeneration of damaged myocardium: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines are disclosed and claimed.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090143294 - Methods of treating vasodilatory shock: The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.... Agent: Polsinelli Shalton Flanigan Suelthaus PC Suite 1100

20090143297 - Modulators of antiestrogen pharmacology: A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes... Agent: Calfee Halter & Griswold, LLP

20090143299 - Novel antimicrobial peptides and use thereof: The invention relates to a molecule comprising at least the amino acid sequence X1 X2 X3 X4 X5 X6 W X8 X9 X10 wherein X4,6,9 is any amino acid residue, X1 is I, L or V, X2 is not C, X3 is A, E, Q, R or Y, X5 is... Agent: Merchant & Gould PC

20090143289 - Orthopoxvirus vectors, genes and products thereof: An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any... Agent: Jacobson Holman PLLC

20090143293 - Peptide inhibitors of protein kinase c gamma for pain management: Peptide sequences derived from the V5 domain of isozymes of protein kinase C for use in pain management are described. Also described are compositions comprising the peptides for treating pain and/or inducing analgesia. Methods of pain treatment and methods of identifying compounds that mimic the activity of the peptides are... Agent: King & Spalding LLP

20090143295 - Peptide-based antiacne reagents: Peptide-based antiacne reagents, formed by coupling a skin-binding peptide with an antiacne agent, are described. The skin-binding peptide portion of the peptide-based antiacne reagent binds strongly to the skin, thus keeping the antiacne agent coupled to the skin for a long lasting effect. Skin care compositions comprising the peptide-based antiacne... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090143288 - Peptide-complement conjugates: The current invention reports a polypeptide conjugate, wherein the conjugate comprises a first polypeptide selected from the group of polypeptides comprising SEQ ID NO: 01 and fragments thereof, and a second polypeptide selected from the group of antifusogenic peptides.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090143283 - Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use: This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of... Agent: Barbara A. Shimei Director, Patents & Licensing

20090143284 - Promoter of regeneration of pancreatic b cell, and promoter of insulin production in pancreatic b cell: A pharmaceutical for promoting neogenesis or regeneration of pancreatic β cells which produces and secretes insulin and for promoting insulin production in β cells, comprising ghrelin or a derivative thereof as an effective component.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090143302 - Pyrimidine compounds: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the... Agent: Occhiuti Rohlicek & Tsao, LLP

20090143285 - Target protein and target gene for drug discovery and screening method: The present invention provides target proteins and target genes for bioactive substances such as drugs, and means that enable the development of novel bioactive substances using the same. More specifically, the present invention provides target proteins and target genes for bioactive substances; screening methods for substances capable of regulating bioactivities;... Agent: Leydig Voit & Mayer, Ltd

20090143287 - Tissue regeneration substrate: The present invention provides a tissue regeneration substrate that has the ability to release a basic fibroblast growth factor (bFGF) and like cell growth factors in a sustained manner, into which cells can easily enter, and that is suitably used for regeneration of tissues. Specifically, the present invention provides a... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090143300 - Treatment of sepsis and septic shock using ghrelin and growth hormone: Methods are disclosed for treating sepsis and septic shock using a combination of ghrelin and growth hormone, and for using ghrelin to reduce organ and tissue injury and improve survival after combined radiation exposure and sepsis.... Agent: Amster, Rothstein & Ebenstein LLP

20090143291 - Tumor antigen based on products of the tumor suppressor gene wt1: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090143290 - Tumor-inhibiting protein and the use thereof: The invention has disclosed a new tumor suppressor protein HCRP1, the polynucleotide sequences encoding this polypeptides, and methods for production of the polypeptide using the recombinant technology. The tumor suppression protein, HCRP1, is obtained through the positional candidate cloning strategy. It locates in 8p22 region of human chromosome. The full... Agent: Osha Liang L.L.P.

20090143303 - Anti-invasive and anti-angiogenic compositions: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as... Agent: Mcdermott, Will & Emery

20090143304 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090143305 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090143306 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090143307 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090143309 - Isozyme-specific antagonists of protein kinase c: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to... Agent: King & Spalding LLP

20090143308 - Yeast membrane protein expression system and its application in drug screening: The invention relates to an in vitro cell based expression system for overexpressing heterologous pump proteins associated with drug resistance into the membrane of the host cell for drug screening applications.... Agent: Jacobson Holman PLLC

20090143310 - Method of stimulating the motility of the gastrointestinal system using ipamorelin: The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable... Agent: Edwards Angell Palmer & Dodge LLP

20090143311 - Compositions comprising tripeptides inhibiting ace: The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament.... Agent: Unilever Patent Group

20090143312 - Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.... Agent: Ropes & Gray LLP

20090143314 - Compositions and methods for combination antiviral therapy: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or... Agent: Gilead Sciences Inc

20090143313 - Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds: An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090143316 - Cocrystal of c-glycoside derivative and l-proline: A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090143315 - Salix extract, its use and formulations containing it: The extract of the invention is characterized by an high content in salicin derivatives, reduced content in high molecular tannins and a content in proanthocyanidins sufficient to inhibit some tissue metal proteases. The product is formulated in oils rich in ω-3 and ω-6 acids which provide a better absorption of... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090143318 - Degranulation inhibitor: e

20090143317 - Quercetin glycoside composition and method of preparing the same: (a) the total proportion of quercetin glycosides in which n is 3, and in which other n values may be 1 or 2, or 1 and 2, is 50 mol % or more, and the total proportion of quercetin glycosides wherein n is 4 or more is 15 mol %... Agent: Drinker Biddle & Reath LLP Attn: Patent Docket Dept.

20090143322 - Cell transfecting formulations of small interfering rna related compositions and methods of making and use: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090143323 - Compositions and methods for inhibiting expression of a gene from the ebola: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.... Agent: Alnylam/fenwick

20090143327 - General composition framework for ligand-controlled regulatory systems: The invention provides an improved design for the construction of extensible nucleic acid-based, ligand-controlled regulatory systems, and the nucleic acid regulatory systems resulting therefrom. The invention contemplates improving the design of the switches (ligand-controlled regulatory systems) through the design of an information transmission domain (ITD). The improved ITD eliminates free-floating... Agent: Ropes & Gray LLP

20090143320 - Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid... Agent: Klauber & Jackson

20090143326 - Micromirs: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.... Agent: Baker Botts L.L.P.

20090143321 - Nucleic acid agents for downregulating h19 and methods of using same: The present invention provides isolated oligonucleotides capable of down-regulating a level of H19 mRNA in cancer cells. Articles of manufacture comprising agents capable of downregulating H19 mRNA in combination with an additional anti-cancer treatment are disclosed as well as methods of treating cancer by administering same.... Agent: Winston & Strawn LLP Patent Department

20090143324 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin... Agent: Sirna Therapeutics, Inc.

20090143325 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin... Agent: Sirna Therapeutics, Inc.

20090143319 - Transcription factor decoy: i

20090143328 - Method of treating cancer by administration of topical active corticosteroids: The present invention provides for methods of treating cancer comprising administering a topical active corticosteroid in conjunction with a form of non-myeloablative conditioning, wherein the above regimen results in a reduction or elimination of cancer cells in an individual.... Agent: Catalyst Law Group, Apc

20090143329 - Gip secretion inhibitor: The present invention provides a postprandial GIP secretion inhibitor comprising potassium alginate as an active ingredient. The postprandial GIP secretion inhibitor of the present invention is useful as a medicine or a food product. The present invention also provides use of potassium alginate for the manufacture of a postprandial GIP... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090143330 - Crystalline polymorphic forms of monosodium n-[-8-(2-hydroxybenzoyl)amino]caprylate: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino] caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form... Agent: Emisphere Technologies, Inc

20090143331 - Polysaccharide gel formulation having increased longevity: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step... Agent: Allergan, Inc.

20090143332 - Cyclodextrin cyanohydrins: The present invention relates to a compound having a cyclodextrin skeleton wherein a hydrogen atom at the C-6 position in at least one of the sugar moieties has been substituted with a cyano group thereby forming a cyanohydrin-type group. The compounds are found to be excellent catalysts, e.g. for the... Agent: Harness, Dickey & Pierce, P.L.C

20090143333 - Silicone gel-based compositions for wound healing and scar reduction: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.... Agent: Mcdermott, Will & Emery

20090143334 - Method of protecting wood through enhanced penetration of wood preservatives and a related solution: A method of protecting wood through enhanced penetration of wood preservatives includes providing a solution including (a) at least one amine oxide. (b) at least one organic wood preservative and (c) a buffering agent. The solution preferably has a pH of about 7 to 10. The solution is applied to... Agent: Eckert Seamans Cherin & Mellott

20090143335 - Modified absorption formulation of gaboxadol: The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or... Agent: Darby & Darby P.C.

20090143336 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090143337 - C2-c5-alkyl-imidazole-bisphosphonates: e

20090143338 - Metal coordinated compositions: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.... Agent: Reed Smith LLP

20090143339 - Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels: Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels in subjects in need thereof are disclosed herein. The methods can be useful for subjects having age related decline in testosterone, exercise induced decline in testosterone, and/or hypogonadism.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090143340 - Pyrocatechin derivatives: t

20090143341 - Microbicidal composition: The invention relates to a microbicidal composition which comprises a mixture of at least two components, the first component being 2-methyl-3-isothiazolone (MIT) and the second component being at least one active compound selected from the following groups of active compounds: a) compound having activated methylol groups b) quats or polyquats... Agent: International Specialty Products William J. Davis, Esq.

20090143342 - 26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin d compounds: where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or when taken together represent the group... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090143343 - Compositions for the treatment of inflammation of the gastrointestinal tract: Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090143344 - Methods for treating or preventing symptoms of hormonal variations: The present invention relates to methods for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one receptor selected... Agent: Howrey LLP-ca

20090143345 - Thioamide derivatives as progesterone receptor modulators: Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.... Agent: Howson & Howson LLP / Wyeth

20090143346 - Method for synthesizing furanosteroids: The present invention is a method for synthesizing furanosteroids. The method involves intramolecular Diels-Alder/retro-Diels-Alder reaction and tautomerization of a functionalized alkyne oxazole to produce a furo[2,3-b]phenol derivative which is elaborated by intermolecular and intramolecular condensations to generate ring-A of the furanosteroid. Furanosteroids and pharmaceutical compositions containing the same are also... Agent: Licata & Tyrrell P.C.

20090143347 - Use of 3-methoxy-pregnenolone for the preparation of a drug for treating depressive disorders and long-term neurological diseases: The invention relates to the therapeutic use of pregnenolone derivatives for treating depressive disorders and long-term neurological diseases.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090143348 - Polysaccharide gel compositions and methods for sustained delivery of drugs: Methods of producing a biocompatible polysaccharide gel composition having sustained release properties are disclosed. Also disclosed is a biocompatible polysaccharide gel composition having sustained release properties, a method of treating a disease or condition using the present biocompatible polysaccharide gel composition, and a method of controlling rate of release of... Agent: Allergan, Inc.

20090143350 - Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods: Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper LLP (us)

20090143349 - Steroid tetrol solid state forms: The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-triol, formulations containing or prepared from such solid state forms and use of such materials for modulating acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity such as arthritis,... Agent: Hollis-eden Pharmaceuticals, Inc.

20090143351 - Substituted azetidinones: Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and... Agent: Morgan, Lewis & Bockius LLP (sf)

20090143352 - Pyrrolo-pyridine kinase modulatiors: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090143353 - Antifungal bicyclic hetero ring compounds: A compound is provided, capable of expressing in a wide spectral range and specifically or selectively, an antifungal effect based on its functional mechanism of 1,6-β-glucan synthesis inhibition. Also provided is a drug, especially an antifungal that contains the compound, its salt or their hydrate. Concretely, provided are a compound... Agent: Sughrue-265550

20090143354 - P2x7 receptor antagonists and their use: The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Fish & Richardson P.C.

20090143355 - Substituted aryl-amine derivatives and methods of use: wherein R, R1 and R2 for each formula are defined herein. The invention further includes analogs, prodrugs and pharmaceutically acceptable salts and derivatives of Formulas I and II, as well as pharmaceutical compositions, medicaments and methods thereof for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer... Agent: Amgen Inc.

20090143356 - Polycylclic carbamoylpyridone derivative having hiv integrase inhibitory acitvity: e

20090143357 - Heteroaryl urea derivatives useful for inhibiting chk1: Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or... Agent: Eli Lilly & Company

20090143358 - Inhibitors of ion channels: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment... Agent: Pfizer Inc.

20090143359 - Percutaneously absorptive ophthalmic preparation comprising epinastine: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises epinastine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising epinastine... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090143362 - Carbamazepine formulations: The present invention relates to a process for preparing a pharmaceutical composition comprising carbamazepine that has a constant release profile.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20090143360 - Oxcarbazepine formulation: The present invention relates to novel uncoated, color-stable tablet formulations comprising oxcarbazepine, a disintegrant and iron oxide pigments. The oxcarbazepine of the present invention has a particle size of about 14 to about 30 microns with a maximum residue on a 40 micron sieve from about 10% to about 35%.... Agent: Venable LLP

20090143361 - Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders.... Agent: Fish & Richardson P.C.

20090143363 - Deuterated lorcaserin: This invention relates to novel compounds that are 3-benzazepine derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 3-benzazepine derivatives that are derivatives of lorcaserin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090143364 - Chiral cis-imidazolines: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090143365 - Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors: The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090143367 - Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10: The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.... Agent: Fish & Richardson P.C.

20090143366 - Chemical compounds: The present invention relates to dihydrobenzodiazepine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dihydrobenzodiazepine derivatives are useful in the treatment of diseases associated with inappropriate ROCK kinase.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090143368 - Use of cinnamoyl compound: e

20090143369 - Methods of using substituted morpholine and thiomorpholine derivatives: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090143370 - Non-nucleoside reverse transcriptase inhibitors: e

20090143371 - Isoxazole-pyridine derivatives:

20090143372 - Chemical compounds: The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090143373 - Quinolone carboxylic acid-substituted rifamycin derivatives: The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the... Agent: Jackson Walker LLP

20090143374 - Use of compounds and compositions for the treatment of amyloid diseases: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, use in the reduction of Aβ peptide in vivo, use in modulating APP processing, and use... Agent: Proteotech, Inc.

20090143375 - Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents: s

20090143376 - Fused heterocyclic compounds and their use as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090143377 - Methods and compositions for treating disorders: Compounds and compositions for treating disorders related to TRPA1 are described herein.... Agent: Lowrie, Lando & Anastasi, LLP

20090143379 - Storage stable perfusion solution for dihydropteridinones: wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090143378 - Thienopyrimidine and thienopyridine kinase modulators: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use... Agent: Philip S. Johnson Johnson & Johnson

20090143380 - 2h- or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof: e

20090143382 - Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses: The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.... Agent: Jones Day

20090143381 - Modulators of atp-binding cassette-transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20090143383 - Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a... Agent: Dykema Gossett PLLC

20090143384 - 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer: The invention concerns pyrimidine derivatives of Formula (I) wherein each of Qa, G1, G2, q, R3, r, R4, X1 and Qb have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in... Agent: Morgan Lewis & Bockius LLP

20090143385 - Isoxazolo-pyridazine derivatives: The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090143386 - Human adam-10 inhibitors: The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination... Agent: Patent Dept Exelixis, Inc.

20090143387 - Sustained-release tablet composition: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet containing reboxetine, or a pharmaceutically acceptable salt thereof, dispersed in a matrix containing a hydrophilic polymer and a starch, wherein the starch has a tensile strength of at least 0.15 kN cm−2 at a solid fraction of 0.75... Agent: Pfizer Inc.

20090143388 - Treatment of brain disorders: Striatal neurodegenerative disorders, e.g. Parkinson's disease, are treated by administration of an effective dose of an antioxidant compound of formula I, formula II or a pharmaceutically acceptable salt thereof, in a regimen that decreases the adverse effects of the disorder. Such adverse effects can motor deficits, which include catalepsy or... Agent: Wilson Sonsini Goodrich & Rosati

20090143389 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using... Agent: Hogan & Hartson LLP

20090143391 - Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10: The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.... Agent: Fulbright & Jaworski, LLP

20090143392 - Methods of treating obesity and metabolic disorders: The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.... Agent: Fish & Richardson P.C.

20090143390 - Parenteral formulations of dopamine agonists: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.... Agent: Darby & Darby P.C.

20090143393 - Method of stimulating hair growth: The present invention is directed to the discovery that (3S,4R)-3,4-dihydro-4-(2,3-dihydro-2-methyl-3-oxopyridazin-6-yl)oxy-3-hydroxy-6-(3-hydroxyphenyl)sulphonyl-2,2,3-trimethyl-2H-benzo[b]pyran may be used to promote hair growth and alleviate alopecia.... Agent: Pfizer Inc.

20090143394 - Compounds for activating tgf-beta signaling: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-β signaling are described.... Agent: King & Spalding LLP

20090143397 - Catechol-based derivatives for treating or preventing diabetics: The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetics and ischemics, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and... Agent: Osha Liang L.L.P.

20090143395 - Piperazine derivatives: e

20090143396 - Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090143398 - Pyrimidinyl-piperazines useful as d3/d2 receptor ligands: wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of... Agent: Fish & Richardson P.C.

20090143399 - Protein kinase inhibitors: e

20090143400 - Purine derivatives having immuno-modulating properties:

20090143401 - Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase:

20090143402 - Isoquinolinone derivatives as nk3 antagonists:

20090143403 - Methods for administering aripiprazole: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests... Agent: Elmore Patent Law Group, PC

20090143404 - Pharmaceutical composition: A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.... Agent: Birch Stewart Kolasch & Birch

20090143405 - Melanin concentrating hormone receptor antagonist: p

20090143406 - New phenylpiperazine:

20090143409 - 3-pyridinecarboxamide derivatives as hdl-cholesterol raising agents:

20090143408 - Compositions and methods for inhibiting cytochrome p450 2d6: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the... Agent: Proskauer Rose LLP

20090143407 - Isoxazolo-pyrazine derivatives: The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention are inverse agonists of GABA A α5. The invention also relates to methods for enhancing... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090143410 - Isoxazolines for controlling invertebrate pests: Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.... Agent: Birch Linda D E I Du Pont De Nemours And Company

20090143411 - Thiophens and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090143412 - Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders: e

20090143413 - Thiazole derivatives as cxcr3 receptor modulators: The invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, which are antagonist of the CXCR3 chemokine receptor useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.... Agent: Merck And Co., Inc

20090143414 - Quinazoline derivatives having tyrosine kinase inhibitory activity: e

20090143415 - Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain: The present invention refers to the use of a sodium channel blocker such as tetrodotoxin or saxitoxin, their analogues and derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics for the treatment of central-nervously derived neuropathic pain.... Agent: Fish & Richardson PC

20090143416 - Method of inducing tolerance of plants against bacterioses: e

20090143417 - Methods of treating pain: The present invention is directed to methods and compositions for inducing, promoting or otherwise facilitating pain relief. More particularly the present invention discloses the combination of a nitric oxide donor and an opioid analgesic in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain,... Agent: Panitch Schwarze Belisario & Nadel LLP

20090143418 - Compositions and methods for preventing and treating hair growth cycle-related conditions: The present invention relates to compositions and methods for the preventing, treating, and researching discoloration (e.g., hair graying, hair whitening, undesired change in hair color). In particular, the present invention provides compositions and methods for treating, preventing and researching hair discoloration through inhibition of mTOR function (e.g., mTOR activity, mTOR... Agent: Casimir Jones, S.c.

20090143419 - Methods and compositions for controlling ectoparasites: A method of treating or preventing ectoparasite infestation in a plant or animal host is provided comprising applying an effective amount of at least one metalloprotease inhibitor and/or at least one metal chelating agent, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously... Agent: Howrey LLP - East

20090143420 - 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof: m

20090143421 - Use of 2-benzoyl-imidazopyridines in therapeutics:

20090143422 - P38 inhibitors and methods of use thereof: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.... Agent: Viksnins Harris & Padys Pllp

20090143423 - Solid dispersion product containing n-aryl urea-based compound: A solid dispersion product comprising at least one N-aryl urea-based pharmaceutically active agent or an agent of related structural type is obtained by a) preparing a liquid mixture containing the at least one active agent, at least one pharmaceutically acceptable matrix-forming agent, at least one pharmaceutically acceptable surfactant and at... Agent: Edwards Angell Palmer & Dodge LLP

20090143424 - Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors: Provided are tetrakis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20090143425 - Compounds affecting gap junction activity: This invention relates to novel quinoline compounds which affect gap junction activity. Also provided are methods of using such compounds and compositions containing the compounds to treat gap junction disorders.... Agent: Greenlee Winner And Sullivan P C

20090143427 - 4-oxoquinoline derivatives: This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention also provides pyrogen-free compositions comprising one or more compounds of this invention and a carrier, and the use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090143426 - Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective et a antagonists and their use as medicaments: The invention discloses the composition and preparation of various 1,3,6-trisubstituted-2-carboxy-quinol-4-ones of the formula 1 where R is H, alkyl, haloalkyl or hydroxyalkyl, R′ is alkyl, nitro, halogen or NR2′″ where R′″ is alkyl or cycloalkyl, and R″ is H or alkyl. The composition of the invented compounds as methods of... Agent: Ralph A. Stephani

20090143428 - Quinoline derivatives 057: The invention provides a compound of formula (I) as defined in the specification, a process for its preparation, pharmaceutical compositions containing it, a process for preparing the pharmaceutical composition, and its use in therapy.... Agent: Fish & Richardson P.C.

20090143429 - Quinoline derivatives as neurokinin receptor antagonists: The present invention relates to substituted quinoline derivatives of Formula (I); wherein hal, n, A, formula (a), R1, R2, R3, R4, R5 and R6 are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used... Agent: Merck And Co., Inc

20090143430 - Erythropoietin production accelerator: e

20090143431 - Pesticide naphthyloxy substituted phenylamidine derivatives: The present invention relates to 2,5-di-substituted-4-naphthyloxy-substituted-phenyl-amidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or damaging insects,... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090143433 - Cocktail for modulation of alzheimer's disease: Formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, i.e., Alzheimer's Disease (AD), Parkinson's Disease, amyotrophic lateral sclerosis, mild cognitive impairment and other types of dementia, comprise therapeutically effective amounts of curcumin, piperine, epigallocatechin-3-gallate (EGCG) and n-acetylcysteine. The combination addresses some or all of the pathways which... Agent: Venable LLP

20090143432 - Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof: The present invention provides a convenient and efficient process for the synthesis of d2-benzo[d][1,3]dioxoles.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090143434 - Methods of using domperidone to terminate acute episodes of cardiac arrhythmia, to restore normal sinus rhythm or heart rate, to prevent recurrence of cardiac arrhythmia and to maintain normal sinus rhythm or heart rate in mammals: Disclosed are methods of terminating acute episodes of cardiac arrhythmia, such as atrial fibrillation or ventricular fibrillation, in a mammal, such as a human, by administering to that mammal an amount of domperidone, or a pharmaceutically acceptable salt, derivative or metabolite thereof, effective to terminate an acute episode of cardiac... Agent: Duane Morris LLP

20090143435 - Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity: The invention provides the use of a non-steroid compound which acts on the GABA receptor for the treatment of disorders relating to reduced neurosteroid activity. The non-steroid compounds may be GABA agonists, GABA uptake inhibitors or enhancers of GABAergic activity.... Agent: Darby & Darby P.C.

20090143436 - Anesthetic composition, formulation and method of use: An anesthetic composition for use e.g. in the administration of a local anesthetic by injection comprises a first component, which comprises hyaluronidase, and a second component which comprises an anesthetic preparation. The composition is both effective and highly shelf stable, and has as an advantage that it may be stored... Agent: Klauber & Jackson

20090143437 - Ep4 receptor antagonists:

20090143438 - Novel pyridine derivative having anti-helicobacter pylori activity: wherein R represents a linear or branched hydroxyalkyl group having 5 to 10 carbon atoms, or a pharmaceutically acceptable salt thereof, which has a potent antibacterial activity against H. pyroli (Helicobacter pyroli) Examples of the disease which can be prevented/treated by administration of a pharmaceutical agent comprising the compound include... Agent: Edwards Angell Palmer & Dodge LLP

20090143439 - New pyridines as fbpase inhibitors for treatment of diabetes: e

20090143440 - Pyrazoles useful in the treatment of inflammation: There is provided compounds of formula (I), wherein R1, R2, X1, X2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly... Agent: Morgan Lewis & Bockius LLP

20090143441 - Combination therapies of thiazolidinedione analogues: The present invention relates to thiazolidinedione analogues that are useful for treating inflammatory disease.... Agent: Honigman Miller Schwartz & Cohn LLP

20090143442 - Thiazolidinedione analogues: The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes.... Agent: Honigman Miller Schwartz & Cohn LLP

20090143444 - Acid secretion inhibitor: wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally... Agent: Edwards Angell Palmer & Dodge LLP

20090143443 - Cyclic amine compound and pest control agent: e

20090143445 - Hdac inhibitors:

20090143446 - Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof:

20090143447 - Seed treatment formulations and methods of use: The present invention generally relates to aqueous seed treatment formulations comprising a pesticidal agent, a polyvinyl alcohol (PVA), a graft copolymer, and a plasticizer. In one embodiment of the invention, PVA-compatible polymer emulsions are employed. The present invention also relates to uses of the disclosed compositions for protecting seeds from... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090143448 - New aminothiazoles as fbpase inhibitors for diabetes: e

20090143449 - Bi-aryl or aryl-heteroaryl substituted indoles: The present invention relates to substituted indoles of Formula (I) useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20090143450 - Method for treating central pain syndrom or for inducing centrally generated pain in an animal model: The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090143451 - Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same: Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a... Agent: Bozicevic, Field & Francis LLP

20090143452 - Use of prochloraz for wood protection: The active compound prochloraz and fungicidal compositions based on prochloraz are highly suitable for protecting wood and timber products against attack and/or destruction by soft-rot fungi.... Agent: Lanxess Corporation

20090143453 - Methods for treating degenerative diseases/injuries: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090143455 - Pyrazoles useful in the treatment of inflammation: v

20090143454 - Pyrazoline derivatives and their use as pesticides:

20090143456 - Polyamine analogs as modulators of cell migration and cell motility: This disclosure relates to methods of inhibiting cell motility or cell migration, and of treating diseases involving cell migration or cell motility, using polyamine analogs, such as conformationally restricted polyamine analogs. The diseases to be treated include immune disorders, inflammatory conditions, infection, abnormal immune responses, undesired angiogenesis, tumor cell metastasis... Agent: Morrison & Foerster LLP

20090143457 - Polycyclic compounds for use in treating ocular neurodegenerative diseases: Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores.... Agent: Walker & Jocke, L.p.a.

20090143459 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms: The present invention provides novel forms of atorvastatin designated Forms VI, VII, VIII, IX, IXa, X, XI, XII, XIV, XVI and XVII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.... Agent: Kenyon & Kenyon LLP

20090143458 - Use of ace inhibitors and/or angiostensin ii receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing: The present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist of the preparation of a medicament for the treatment of skin ageing or wrinkling. Furthermore, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090143460 - Novel polymorphic form of rotigotine and process for production: The present invention relates to a novel polymorphic form of rotigotine characterized by at least one of the following powder X-ray diffraction peaks: 12.04, 13.68, 17.72 and 19.01±0.2 (° 2θ), measured with a Cu—Kα irradiation (1.54060 Å), and a process for production thereof, which is useful for the manufacture of... Agent: Harness, Dickey, & Pierce, P.l.c

20090143461 - Substituted cyclopentanes having prostaglandin activity: e

20090143462 - Products of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same: Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the transdermal administration of a Δ9-THC prodrug for treating and preventing diseases and/or disorders.... Agent: Mayer Brown LLP

20090143463 - Therapeutic agent and treatment method for ameliorating uremia: A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as... Agent: Ip Group Of Dla Piper US LLP

20090143464 - Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent: A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compounds, taxanes, epothilone class, vinca alkaloids, said method comprising the administration in a co-ordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said... Agent: Nixon & Vanderhye, PC

20090143465 - Ester compound and its use in pest control: m

20090143466 - Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy: A method for isolating atraric acid from biological material, atraric acid derivatives, the chemical synthesis thereof, and the use of atraric acid and the derivatives thereof for treating or producing a medicament for treating benign prostate hyperplasia, prostate carcinoma or spinobulbar muscular atrophy is provided. In addition, a basic substance... Agent: D. Peter Hochberg Co. L.p.a.

20090143467 - Anticancer agents based on regulation of protein prenylation: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the... Agent: Banner & Witcoff, Ltd.

20090143468 - Pet food compositions and methods: In yet another embodiment, the disclosure is directed to methods selected from promoting bone or joint health, promoting chondrocyte functioning, maintaining tissue concentration of omega-3 fatty acids, promoting tissue concentration of omega-3 fatty acids, and combinations thereof, including the like, in a pet, comprising administration of a composition comprising SDA... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090143469 - Salts of nateglinide: The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular disease, or conditions associated therewith.... Agent: Novartis Corporate Intellectual Property

20090143470 - Invisible antimicrobial glove and hand antiseptic: An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the... Agent: David W. Highet, Vp & ChiefIPCounsel Becton, Dickinson And Company

20090143472 - Intermediate compounds and their use in preparation of lacosamide:

20090143471 - Process for the atomization of ioxilan: The invention relates to a process for the preparation of ioxilan of formula 5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-N-(2,3-dihydroxypropyl)-N′-(2-hydroxyethyl)isophthalamide by atomization and to the improved product thus obtained. This process makes it possible to avoid a process by crystallization and results in an active principle having an improved solubility.... Agent:

20090143473 - Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids: e

20090143474 - Reduced dose intravenous acetaminophen: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.... Agent: Wilson Sonsini Goodrich & Rosati

20090143475 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20090143476 - Antimicrobial nanoemulsion compositions and methods: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present... Agent: Casimir Jones, S.c.

20090143477 - Antimicrobial nanoemulsion compositions and methods: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present... Agent: Casimir Jones, S.c.

20090143478 - Milled submicron organic biocides with narrow particle size distribution, and uses thereof: A method of milling substantially insoluble solid organic biocides to form a micron or sub-micron product having a narrow particle size distribution is presented. The milling involves wet milling of the organic biocide with high density milling media having a diameter between 0.1 mm and 0.8 mm, preferably between 0.2... Agent: Morgan Lewis & Bockius LLP

20090143479 - Pharmaceutical compositions comprising terbinafine: This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration.... Agent: Novartis Corporate Intellectual Property

20090143480 - Use of rr/sr-ractopamine: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.... Agent: Nields, Lemack & Frame, LLC

20090143481 - Methods for washing carcasses, meat, or meat products with medium chain peroxycarboxlyic acid compositions: The present invention relates to methods for reducing microbial contamination on carcass, meat, or meat product; or on surfaces used in processing the carcass, meat, or meat product; employing compositions including medium chain peroxycarboxylic acid, and to the compositions. The methods include applying a medium chain peroxycarboxylic acid composition to... Agent: Ecolab Inc.

20090143482 - Pesticidal substituted phenylethers: The invention relates to the use of phenylether derivatives of formula (I), to compositions thereof for the control of pests, including arthropods and helminths.... Agent: Thomas J. Kowalski Frommer Lawrence And Haug

20090143483 - Therapeutic or preventive drug for osteoporosis comprising isotaxiresinol derived from taxus yunnanensis: e

20090143484 - Use of garlic oil to increase bioavailability of coenzyme q-10: The invention describes compositions that include a sulfide containing molecule, such a garlic oil, and a coenzyme Q molecule. The sulfide containing molecule solvates the coenzyme Q molecule, thus enhancing the bioavailability of the coenzyme Q molecule in a subject in need thereof, relative to administration of coenzyme Q devoid... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090143485 - Optically active muscone composition and fragrances or cosmetics containing the same: (Means for Resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture... Agent: Fitzpatrick Cella Harper & Scinto

20090143486 - Charge reversible polymers: Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20090143487 - Enhanced stability of proteins immobilized on nanoparticles: This invention is directed to the application of a previously unknown property of nanomaterials—its ability to enhance protein activity and stability at high temperatures, in organic solvents, and in polymer composites. Nanomaterials such as single-walled carbon nanotubes (SWNTs) can significantly enhance enzyme function and stability in strongly denaturing environments. Experimental... Agent: Elmore Patent Law Group, PC

20090143488 - Peptides imparting umami, salt, dairy and bitter flavor: The invention relates to compositions and methods of using the flavor active peptides, Lys-Ile-His-Pro-Phe (SEQ ID NO:1), Gly-Pro-Phe-Pro-Ile (SEQ ID NO:2), and Lys-Lys-Tyr-Lys-Val-Pro-Gln (SEQ ID NO:3), to impart a bitter, salt, dairy or umami flavor to food or pharmaceutical products. In particular embodiments, the Lys-Lys-Tyr-Lys-Val-Pro-Gln (SEQ ID NO:3) peptide further... Agent: Licata & Tyrrell P.C.

20090143489 - Preservatives for cosmetic, toiletry and pharmaceutical compositions: A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to... Agent: Flaster/greenberg P.C. 8 Penn Center

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140925: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.65103 seconds

PATENT INFO